Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1485).(02). Dermatology Department Case No (106): Undifferentiated Genital Ulcer Disease with Associated Skin Rash and Generalized Weakness Suspected Syphilis versus Genital Herpes; Possible Secondary Bacterial Infection (1 PR+ 0RE + 0Img)7799

Prescription attached:-

đŸŠē LIPU MED — COMPLETE CLINICAL CASE REVIEW

Prescription Analysis | Clinical Diagnosis | Evidence-Based Management | MedEx Bangladesh | 10 Clinical Decision-Making Modules

🟧 PROPOSED WEBSITE PUBLICATION TITLE

TC(1485).(02). Dermatology Department Case No (106): Undifferentiated Genital Ulcer Disease with Associated Skin Rash and Generalized Weakness — Suspected Syphilis versus Genital Herpes; Possible Secondary Bacterial Infection — Clinical Diagnosis, Prescription Safety Review and Guideline-Based Management (1 Prescription + 0 Reports + 0 Clinical Images)

āĻŦāĻžāĻ‚āϞāĻž āĻļāĻŋāϰ⧋āύāĻžāĻŽ

āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž, āĻļāϰ⧀āϰ⧇ āĻ°â€ā§āϝāĻžāĻļ āĻ“ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻœā§‡āύāĻŋāϟāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ āĻāĻŦāĻ‚ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟, āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻžāĨ¤

Department: Dermatology & Venereology — āϚāĻ°ā§āĻŽ āĻ“ āϝ⧌āύāϰ⧋āĻ— āĻŦāĻŋāĻ­āĻžāĻ—āĨ¤

DCS: 02
Proposed TC: 1485
Proposed Department Case Number: 106

Case type: Prescription-based clinical assessment.

Evidence available: One prescription. No investigation results or clinical photographs.

Diagnostic certainty: Provisional / Working Diagnosis.

Confidence: 0.99 for documented clinical syndrome; etiological diagnosis remains unconfirmed.


🟧 SECTION 1. ORIGINAL PRESCRIPTION INFORMATION

1.1 Patient Information — āϰ⧋āĻ—ā§€āϰ āĻĒāϰāĻŋāϚāĻŋāϤāĻŋ

ParameterOriginal InformationāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨConfidence
Patient NameNazem AliāύāĻžāĻœā§‡āĻŽ āφāϞ⧀0.99
SexMaleāĻĒ⧁āϰ⧁āώ0.99
Age52 yearsā§Ģ⧍ āĻŦāĻ›āϰ0.99
Weight65 kgā§Ŧā§Ģ āϕ⧇āϜāĻŋ0.99
Consultation Date20 October 2026⧍ā§Ļ āĻ…āĻ•ā§āĻŸā§‹āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ0.99
Prescription TypeOutpatient prescriptionāĻŦāĻšāĻŋāĻ°ā§āĻŦāĻŋāĻ­āĻžāϗ⧇āϰ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ0.95
Physician’s DxNot documentedāϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϰ⧋āϗ⧇āϰ āύāĻžāĻŽ āϞ⧇āϖ⧇āύāύāĻŋ0.99
Investigation ResultsNot attachedāĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāύāĻŋ0.99

1.2 Original Prescribing Doctor — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϤāĻĨā§āϝ

Name: Dr. Mamunur Rashid — āĻĄāĻžāσ āĻŽāĻžāĻŽā§āύ⧁āϰ āϰāĻļā§€āĻĻāĨ¤

Visible qualifications: MBBS (Dhaka), BCS (Health)āĨ¤ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āφāϰāĻ“ āĻ•āĻŋāϛ⧁ āĻĒā§āϰāĻļāĻŋāĻ•ā§āώāĻŖāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āϤāĻĨā§āϝ āĻ°ā§Ÿā§‡āϛ⧇, āϤāĻŦ⧇ āϏāĻŦāϗ⧁āϞ⧋ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻ¸ā§āĻĒāĻˇā§āϟ āύ⧟āĨ¤

Designation: Medical Officer — āĻŽā§‡āĻĄāĻŋāϕ⧇āϞ āĻ…āĻĢāĻŋāϏāĻžāϰāĨ¤

Institution: Bauphal Upazila Health Complex, Bauphal, Patuakhali — āĻŦāĻžāωāĻĢāϞ āωāĻĒāĻœā§‡āϞāĻž āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ āĻ•āĻŽāĻĒā§āϞ⧇āĻ•ā§āϏ, āĻŦāĻžāωāĻĢāϞ, āĻĒāϟ⧁⧟āĻžāĻ–āĻžāϞ⧀āĨ¤

Chamber: BOGA DIGITAL DIAGNOSTIC CENTER — āĻŦāĻ—āĻž āĻĄāĻŋāϜāĻŋāϟāĻžāϞ āĻĄāĻžā§ŸāĻžāĻ—āύāĻ¸ā§āϟāĻŋāĻ• āϏ⧇āĻ¨ā§āϟāĻžāϰ, āĻŦāĻ—āĻž āĻŦāĻžāϜāĻžāϰ, āĻŦāĻžāωāĻĢāϞ, āĻĒāϟ⧁⧟āĻžāĻ–āĻžāϞ⧀āĨ¤

BMDC registration: Printed on the original prescription; exact digits should be confirmed from the source before transcription.

Confidence: 0.98 for clearly legible information.

Publication privacy statement: āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϰ⧋āĻ—ā§€ āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻžāĻŽ āĻāχ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻžā§Ÿ āĻ…āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāĻŋāϤ āϰāĻžāĻ–āĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āϰ⧋āĻ—ā§€āϰ āϝ⧌āύāĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āϤāĻĨā§āϝ āĻāĻŦāĻ‚ āĻĒāϰāĻŋāϚ⧟ āωāĻ¨ā§āĻŽā§āĻ•ā§āϤ āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāĻŸā§‡ āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āφāϗ⧇ āϝāĻĨāĻžāϝāĻĨ āϞāĻŋāĻ–āĻŋāϤ āϏāĻŽā§āĻŽāϤāĻŋ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤


🟧 SECTION 2. CHIEF COMPLAINTS — C/C

C/C means Chief Complaints — āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—āĨ¤

āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϤāĻŋāύāϟāĻŋ āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ— āϞāĻŋāϖ⧇āϛ⧇āύāĨ¤

No.Original C/CClinical MeaningāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨConfidence
1G. WeaknessGeneralized weaknessāϏāĻžāĻ°ā§āĻŦāĻŋāĻ• āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž0.98
2Ulcer on private partGenital ulcerationāϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž0.99
3Skin rashCutaneous rashāĻļāϰ⧀āϰ⧇āϰ āĻ¤ā§āĻŦāϕ⧇ āĻ°â€ā§āϝāĻžāĻļ āĻŦāĻž āĻĢ⧁āϏāĻ•ā§ā§œāĻŋ0.99

2.1 Generalized Weakness — āϏāĻžāĻ°ā§āĻŦāĻŋāĻ• āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž

Definition: A subjective feeling of reduced physical energy or strength.

āĻŦāĻžāĻ‚āϞāĻž: āĻļāϰ⧀āϰ⧇āϰ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻļāĻ•ā§āϤāĻŋ āĻŦāĻž āĻ•āĻ°ā§āĻŽāĻ•ā§āώāĻŽāϤāĻž āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžāϰ āĻ…āύ⧁āĻ­ā§‚āϤāĻŋāĨ¤

Possible etiology: Anaemia, infection, malnutrition, endocrine disease, diabetes and various systemic illnesses.

āĻŦāĻžāĻ‚āϞāĻž: āϰāĻ•ā§āϤāĻ¸ā§āĻŦāĻ˛ā§āĻĒāϤāĻž, āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āĻĒ⧁āĻˇā§āϟāĻŋāϰ āϘāĻžāϟāϤāĻŋ, āĻšāϰāĻŽā§‹āύāϜāύāĻŋāϤ āϰ⧋āĻ—, āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏāϏāĻš āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻ•āĻžāϰāϪ⧇ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Clinical interpretation: Weakness is nonspecific and does not identify the underlying disease.

āĻŦāĻžāĻ‚āϞāĻž: āĻļ⧁āϧ⧁ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻĻ⧇āϖ⧇ āϰ⧋āϗ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ•āĻžāϰāĻŖ āĻŦāϞāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

Patient-specific confidence: 0.99 for the complaint; below 0.40 for any specific cause.

2.2 Genital Ulcer — āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž

Definition: Loss of continuity of genital skin or mucosal epithelium producing an open lesion.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āĻ¤ā§āĻŦāĻ• āĻŦāĻž āĻļā§āϞ⧇āĻˇā§āĻŽāĻžāĻāĻŋāĻ˛ā§āϞāĻŋāϰ āωāĻĒāϰāĻŋāĻ­āĻžāĻ— āύāĻˇā§āϟ āĻšā§Ÿā§‡ āĻ–ā§‹āϞāĻž āĻ•ā§āώāϤ āϤ⧈āϰāĻŋ āĻšāĻ“ā§ŸāĻžāĨ¤

Possible causes: Syphilis, genital herpes, other sexually transmitted infections, trauma, fixed drug eruption, inflammatory disorders and malignancy.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ, āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āφāϘāĻžāϤ, āĻ“āώ⧁āϧ⧇āϰ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž, āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āĻ•ā§āϝāĻžāύāϏāĻžāϰāϜāύāĻŋāϤ āĻ•āĻžāϰāϪ⧇ āϘāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Clinical significance: Anogenital ulcers require structured evaluation because clinical appearance alone can be unreliable.

āĻŦāĻžāĻ‚āϞāĻž: āϘāĻž āĻĻ⧇āĻ–āϤ⧇ āϕ⧇āĻŽāύ, āĻŦā§āϝāĻĨāĻž āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ āϕ⧋āύ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āĻ•ā§€â€”āĻāϏāĻŦ āĻ›āĻžā§œāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻ•āϰāĻž āĻ•āĻ āĻŋāύāĨ¤

Confidence: 0.99 for need for evaluation.

2.3 Skin Rash — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ°â€ā§āϝāĻžāĻļ

Definition: A visible alteration in skin colour, texture or surface morphology.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇ āϞāĻžāϞāĻšā§‡ āĻĻāĻžāĻ—, āĻĢ⧁āϏāĻ•ā§ā§œāĻŋ, āϚāĻžāĻ•āĻž āĻŦāĻž āĻ…āĻ¨ā§āϝ āϧāϰāύ⧇āϰ āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύāĨ¤

Possible causes: Infection, allergy, drug reactions and inflammatory skin disease.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ, āĻ“āώ⧁āϧ⧇āϰ āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻ…āĻĨāĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āϚāĻ°ā§āĻŽāϰ⧋āĻ—āĨ¤

Clinical significance: Generalized rash with genital ulceration raises concern for secondary syphilis, but the rash and ulcer may also have unrelated causes.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž āĻ“ āĻļāϰ⧀āϰ⧇ āĻ°â€ā§āϝāĻžāĻļ āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻĨāĻžāĻ•āϞ⧇ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤ āϤāĻŦ⧇ āĻĻ⧁āϟāĻŋ āωāĻĒāϏāĻ°ā§āĻ— āĻāĻ•āχ āϰ⧋āϗ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻšā§Ÿā§‡āĻ›ā§‡â€”āĻāϟāĻŋ āĻāĻ–āύ⧋ āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āύ⧟āĨ¤

Confidence: 0.95 for clinical relevance; 0.70 for syphilis being a leading differential.


🟧 SECTION 3. ORIGINAL CLINICAL OBSERVATION — O/E

O/E means On Examination — āϰ⧋āĻ—ā§€ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖāĨ¤

ParameterOriginal RecordClinical MeaningāĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻžConfidence
O/ENADNo abnormality detectedāϏāĻžāϧāĻžāϰāĻŖ āĻĒāϰ⧀āĻ•ā§āώāĻžā§Ÿ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āϤāĻž āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ0.99
Blood PressureApproximately 130/80 mmHgBlood pressureāϰāĻ•ā§āϤāϚāĻžāĻĒ āφāύ⧁āĻŽāĻžāύāĻŋāĻ• ā§§ā§Šā§Ļ/ā§Žā§Ļ0.85
PulseNot writtenPulse not recordedāύāĻžā§œāĻŋāϰ āĻ—āϤāĻŋ āϞ⧇āĻ–āĻž āύ⧇āχ0.99
TemperatureUnclear symbolNo reliable numeric valueāϤāĻžāĻĒāĻŽāĻžāĻ¤ā§āϰāĻžāϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŽāĻžāύ āĻŦā§‹āĻāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻž0.95
HeartAppears to indicate S1/S2; full notation unclearBasic cardiac auscultationāĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻļāĻŦā§āĻĻ āĻĒāϰ⧀āĻ•ā§āώāĻž0.70
LungAppears clinically unremarkableLung examinationāĻĢ⧁āϏāĻĢ⧁āϏ⧇āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžā§Ÿ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āϤāĻž āϞ⧇āĻ–āĻž āύ⧇āχ āĻŦāϞ⧇ āĻŽāύ⧇ āĻšāĻšā§āϛ⧇0.75
Genital lesionNot describedSpecific examination absentāϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻžā§Ÿā§‡āϰ āĻŦāĻŋāĻŦāϰāĻŖ āύ⧇āχ0.99
Skin rashNot characterizedRash morphology absentāĻ°â€ā§āϝāĻžāĻļ⧇āϰ āĻĒā§āϰāĻ•ā§ƒāϤāĻŋ āϞ⧇āĻ–āĻž āύ⧇āχ0.99

Clinical Observation Analysis

Finding 1: O/E: NAD does not rule out genital ulcer disease.

āĻŦāĻžāĻ‚āϞāĻž: NAD āϞ⧇āĻ–āĻž āĻĨāĻžāĻ•āϞ⧇āĻ“ āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āύ⧇āχ āĻ•āĻŋāĻ‚āĻŦāĻž STI āύ⧇āĻ‡â€”āĻāĻŽāύ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āĻĻ⧇āĻ“ā§ŸāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

Finding 2: Genital lesion morphology has not been documented.

āĻŦāĻžāĻ‚āϞāĻž: āϘāĻž āĻŦā§āϝāĻĨāĻžāϝ⧁āĻ•ā§āϤ āĻ•āĻŋ āύāĻž, āĻāĻ•āϟāĻŋ āύāĻž āĻāĻ•āĻžāϧāĻŋāĻ•, āϕ⧋āĻĨāĻžā§Ÿ, āĻ•āϤ āĻŦ⧜ āĻāĻŦāĻ‚ āϕ⧀ āϧāϰāύ⧇āĻ°â€”āĻāϗ⧁āϞ⧋āϰ āϕ⧋āύ⧋ āϤāĻĨā§āϝ āύ⧇āχāĨ¤

Finding 3: The rash distribution is unknown.

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāϤ⧇āϰ āϤāĻžāϞ⧁, āĻĒāĻžā§Ÿā§‡āϰ āϤāϞāĻž, āĻŦ⧁āĻ•, āĻĒāĻŋāĻ  āĻ…āĻĨāĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āĻĨāĻžā§Ÿ āĻ°â€ā§āϝāĻžāĻļ āĻšā§Ÿā§‡āϛ⧇ āϤāĻž āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Clinical significance: These omissions substantially limit diagnostic accuracy.

Confidence: 0.99.


🟧 SECTION 4. COMPLETE HISTORY ASSESSMENT

Documented and Missing Clinical Histories

ParameterEnglish MeaningāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨPrescription Status
I/HIllness/Infection History, depending on local notationāĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ…āϏ⧁āĻ¸ā§āĻĨāϤāĻž āĻŦāĻž āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
O/HOccupational or Other HistoryāĻĒ⧇āĻļāĻžāĻ—āϤ āĻŦāĻž āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āχāϤāĻŋāĻšāĻžāϏNot documented
D/HDrug HistoryāĻ“āώ⧁āϧ āĻ—ā§āϰāĻšāϪ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
M/HMedical HistoryāĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
P/HPast HistoryāĻ…āϤ⧀āϤ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
F/HFamily HistoryāĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ• āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
S/HSexual/Social Historyāϝ⧌āύ āĻ“ āϏāĻžāĻŽāĻžāϜāĻŋāĻ• āχāϤāĻŋāĻšāĻžāϏNot documented
O/S/EOther Systemic ExaminationāĻļāϰ⧀āϰ⧇āϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…āĻ™ā§āϗ⧇āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžNot separately documented
O/G/EMeaning not defined in the original prescriptionāϏāĻ‚āĻ•ā§āώāĻŋāĻĒā§āϤ āϰ⧂āĻĒāϟāĻŋāϰ āĻ…āĻ°ā§āĻĨ āĻāĻ–āĻžāύ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟Not documented
Allergy HistoryDrug or other allergy historyāĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āχāϤāĻŋāĻšāĻžāϏNot documented
Surgical HistoryPrevious surgical historyāĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ…āĻĒāĻžāϰ⧇āĻļāύ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
Immunization HistoryVaccination historyāϟāĻŋāĻ•āĻž āύ⧇āĻ“ā§ŸāĻžāϰ āχāϤāĻŋāĻšāĻžāϏNot documented

Documentation confidence: 0.99.

History Required for Clinical Diagnosis

1. Duration of genital ulcer — āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž āĻ•āϤāĻĻāĻŋāύ āϧāϰ⧇?

Ulcer onset and progression help distinguish acute from chronic disease.

āϘāĻž āĻ•āĻ–āύ āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻĻāĻŋāύ āĻĻāĻŋāύ āĻŦāĻžā§œāϛ⧇ āύāĻžāĻ•āĻŋ āĻ•āĻŽāĻ›ā§‡â€”āĻāϟāĻŋ āϜāĻžāύāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

2. Pain and tenderness — āϘāĻžā§Ÿā§‡ āĻŦā§āϝāĻĨāĻž āφāϛ⧇ āĻ•āĻŋ?

Syphilitic chancres are often painless; HSV lesions are often painful. However, these are tendencies rather than definitive diagnostic rules.

āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇āϰ āϘāĻž āĻ…āύ⧇āĻ• āϏāĻŽā§Ÿ āĻŦā§āϝāĻĨāĻžāĻšā§€āύ āĻāĻŦāĻ‚ āĻšāĻžāϰāĻĒāĻŋāϏ⧇āϰ āϘāĻž āĻ…āύ⧇āĻ• āϏāĻŽā§Ÿ āĻŦā§āϝāĻĨāĻžāϝ⧁āĻ•ā§āϤ āĻšā§ŸāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻļ⧁āϧ⧁ āĻŦā§āϝāĻĨāĻž āĻĻāĻŋā§Ÿā§‡ āύāĻŋāĻļā§āϚāĻŋāϤ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύ⧇āĻ“ā§ŸāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

3. Vesicles — āĻĢā§‹āϏāĻ•āĻž āĻšā§Ÿā§‡āĻ›āĻŋāϞ āĻ•āĻŋ?

Grouped vesicles preceding ulceration support HSV infection.

āϘāĻž āĻšāĻ“ā§ŸāĻžāϰ āφāϗ⧇ āĻĒāĻžāύāĻŋāĻ­āϰāĻž āĻĢā§‹āϏāĻ•āĻž āĻĨāĻžāĻ•āϞ⧇ āĻšāĻžāϰāĻĒāĻŋāϏ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŦāĻžā§œā§‡āĨ¤

4. Previous sexual exposure — āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϝ⧌āύ-āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ⧇āϰ āχāϤāĻŋāĻšāĻžāϏāĨ¤

A confidential, nonjudgmental assessment is relevant for STI risk evaluation.

āĻ—ā§‹āĻĒāĻ¨ā§€ā§ŸāϤāĻž āĻŦāϜāĻžā§Ÿ āϰ⧇āϖ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āϝ⧌āύāĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āύāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

5. Previous STI treatment — āφāϗ⧇ āϝ⧌āύāĻŦāĻžāĻšāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ?

Past syphilis treatment affects interpretation of treponemal serology.

āφāϗ⧇ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϞ⧇ āϰāĻ•ā§āϤāĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āĻŦā§āϝāĻžāĻ–ā§āϝāĻžā§Ÿ āϤāĻžāϰ āĻĒā§āϰāĻ­āĻžāĻŦ āĻĒā§œā§‡āĨ¤

6. Rash distribution — āĻ°â€ā§āϝāĻžāĻļ āϕ⧋āĻĨāĻžā§Ÿ āϕ⧋āĻĨāĻžā§Ÿ?

Palms, soles, mucous membranes and generalized distribution are clinically relevant.

āĻšāĻžāϤ⧇āϰ āϤāĻžāϞ⧁, āĻĒāĻžā§Ÿā§‡āϰ āϤāϞāĻž āĻŦāĻž āĻŽā§āϖ⧇ āĻĻāĻžāĻ— āĻĨāĻžāĻ•āϞ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

7. Diabetes and HIV status — āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ āĻ“ HIV-āĻāϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāĨ¤

These may affect infection severity and healing.

āĻ•āĻŋāϛ⧁ āϰ⧋āϗ⧇ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦ⧇āĻļāĻŋ āϜāϟāĻŋāϞ āĻšāϤ⧇ āĻĒāĻžāϰ⧇ āĻāĻŦāĻ‚ āϘāĻž āĻļ⧁āĻ•āĻžāϤ⧇ āϏāĻŽā§Ÿ āϞāĻžāĻ—āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.98 for relevance of history collection.

Important: āĻāϗ⧁āϞ⧋ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒā§āϰāĻļā§āύ; āϰ⧋āĻ—ā§€āϰ āĻ•āĻžāĻ› āĻĨ⧇āϕ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āωāĻ¤ā§āϤāϰ āύ⧟āĨ¤


🟧 SECTION 5. INVESTIGATIONS AND CLINICAL INTERPRETATION

5.1 Investigations Ordered by the Doctor

Investigation 1 — CBC

Full Form: Complete Blood Count.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āϰāĻ•ā§āϤāĻ•āĻŖāĻŋāĻ•āĻž āĻ—āĻŖāύāĻžāĨ¤

Clinical purpose: Assessment of haemoglobin, white blood cells and platelet count.

āĻŦāĻžāĻ‚āϞāĻž: āϰāĻ•ā§āϤāĻ¸ā§āĻŦāĻ˛ā§āĻĒāϤāĻž, āϰāĻ•ā§āϤ⧇āϰ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āϕ⧋āώ⧇āϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻāĻŦāĻ‚ āĻĒā§āϞ⧇āϟāϞ⧇āĻŸā§‡āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āύāĻŋāĻ°ā§āϪ⧟āĨ¤

Patient-specific importance: Weakness is present, and prolonged linezolid exposure can affect blood-cell production.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻāĻŦāĻ‚ Linezolid-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰāĻ•ā§āϤāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāϪ⧇ CBC āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Doctor ordered: Yes.

Result available: No.

Confidence: 0.99.

Investigation 2 — VDRL

Full Form: Venereal Disease Research Laboratory test.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āύāύ-āĻŸā§āϰ⧇āĻĒā§‹āύ⧇āĻŽāĻžāϞ āϰāĻ•ā§āϤāĻĒāϰ⧀āĻ•ā§āώāĻžāĨ¤

Clinical purpose: Screening/assessment of syphilis and quantitative monitoring when reported with titres.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡ āϏāĻšāĻžā§ŸāϤāĻž āĻāĻŦāĻ‚ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻĒāϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ titre āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖāĨ¤

Patient-specific importance: Genital ulcer and rash together make syphilis an important differential.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āĻ“ āĻ°â€ā§āϝāĻžāĻļ⧇āϰ āĻ•āĻžāϰāϪ⧇ VDRL āĻĒāϰ⧀āĻ•ā§āώāĻž āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤāĨ¤

Doctor ordered: Yes.

Result available: No.

Confidence: 0.99.

Important Limitation

A VDRL result alone cannot reliably establish or exclude syphilis.

āĻŦāĻžāĻ‚āϞāĻž: VDRL positive āĻšāϞ⧇āχ āϏāĻ•ā§āϰāĻŋ⧟ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āύāĻŋāĻļā§āϚāĻŋāϤ āĻšā§Ÿ āύāĻž āĻāĻŦāĻ‚ negative āĻšāϞ⧇āχ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āĻĒāĻ°ā§āϝāĻžā§Ÿā§‡āϰ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻĒ⧁āϰ⧋āĻĒ⧁āϰāĻŋ āĻŦāĻžāĻĻ āϝāĻžā§Ÿ āύāĻžāĨ¤

Nontreponemal testing should be interpreted alongside a treponemal assay and relevant clinical history.

āĻŦāĻžāĻ‚āϞāĻž: VDRL/RPR-āĻāϰ āϏāĻ™ā§āϗ⧇ TPPA āĻ…āĻĨāĻŦāĻž āĻ…āĻ¨ā§āϝ āωāĻĒāϝ⧁āĻ•ā§āϤ treponemal test āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Evidence: CDC Laboratory Recommendations for Syphilis Testing, 2024.

5.2 Additional Investigations Recommended

TestEnglish PurposeāĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻžPriority
Quantitative RPR/VDRLBaseline syphilis titreāϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇āϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• titre āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖHigh
TPPA or treponemal EIATreponemal confirmationāϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻĄāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻžHigh
HSV-1/HSV-2 PCR from lesionDetect herpesvirus DNAāϘāĻž āĻĨ⧇āϕ⧇ āĻšāĻžāϰāĻĒāĻŋāϏ āĻ­āĻžāχāϰāĻžāϏ āĻļāύāĻžāĻ•ā§āϤHigh if lesion available
HIV Ag/AbScreen for HIV infectionHIV āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻĒāϰ⧀āĻ•ā§āώāĻžHigh
CBC with plateletsAnaemia and linezolid monitoringāϰāĻ•ā§āϤāĻ¸ā§āĻŦāĻ˛ā§āĻĒāϤāĻž āĻ“ Linezolid āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āϝāĻžāϚāĻžāχHigh
Fasting glucose/HbA1cAssess diabetesāĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύConditional
Bacterial cultureIdentify bacterial pathogenāĻĒ⧁āρāϜ āĻŦāĻž āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻĨāĻžāĻ•āϞ⧇ āĻœā§€āĻŦāĻžāϪ⧁ āĻļāύāĻžāĻ•ā§āϤConditional
Renal functionAssess kidney functionāĻ•āĻŋāĻĄāύāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āύāĻŋāĻ°ā§āϪ⧟Conditional
Lesion biopsyEvaluate atypical/nonhealing lesionsāĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻŦāĻž āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āϘāĻž āĻĒāϰ⧀āĻ•ā§āώāĻžConditional

Confidence: 0.95–0.99 depending on clinical indication.


🟧 SECTION 6. DEFINITION, ETIOLOGY AND PATHOPHYSIOLOGY

6.1 Genital Ulcer Disease — āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž

Definition: A clinical syndrome involving ulcerative lesions of the genital or adjacent anogenital region.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āĻ— āĻ…āĻĨāĻŦāĻž āϤāĻžāϰ āφāĻļāĻĒāĻžāĻļ⧇ āĻ•ā§āώāϤ āĻŦāĻž āφāϞāϏāĻžāϰ āϏ⧃āĻˇā§āϟāĻŋāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻĒā§āϰāĻ•āĻžāĻļ āĻĒāĻžāĻ“ā§ŸāĻž āĻāĻ•āϟāĻŋ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŽāĻ¸ā§āϝāĻžāĨ¤

Etiology: Infectious and noninfectious causes.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāϜāύāĻŋāϤ āĻāĻŦāĻ‚ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĻŦāĻŋāĻšā§€āύ āωāϭ⧟ āĻ•āĻžāϰāĻŖ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Pathophysiology: Damage to epidermal or mucosal integrity results in ulcer formation through infection, inflammation, trauma or other tissue-destructive processes.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āφāϘāĻžāϤ⧇ āĻ¤ā§āĻŦāĻ• āĻ“ āĻļā§āϞ⧇āĻˇā§āĻŽāĻžāĻāĻŋāĻ˛ā§āϞāĻŋāϰ āϕ⧋āώ āĻ•ā§āώāϤāĻŋāĻ—ā§āϰāĻ¸ā§āϤ āĻšāϞ⧇ āϘāĻž āϤ⧈āϰāĻŋ āĻšā§ŸāĨ¤

Clinical features: Painful or painless ulcer, erythema, discharge, vesicles or lymphadenopathy depending on cause.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻĨāĻžāϝ⧁āĻ•ā§āϤ āĻŦāĻž āĻŦā§āϝāĻĨāĻžāĻšā§€āύ āϘāĻž, āϞāĻžāϞāĻ­āĻžāĻŦ, āĻĒ⧁āρāϜ, āĻĢā§‹āϏāĻ•āĻž āĻ…āĻĨāĻŦāĻž āϕ⧁āρāϚāĻ•āĻŋāϰ āϞāĻŋāĻŽā§āĻĢ āύ⧋āĻĄ āĻĢ⧁āϞ⧇ āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.99 for general medical description.

6.2 Syphilis — āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ

Definition: A bacterial sexually transmitted infection caused by Treponema pallidum.

āĻŦāĻžāĻ‚āϞāĻž: āĻŸā§āϰ⧇āĻĒā§‹āύ⧇āĻŽāĻž āĻĒā§āϝāĻžāϞāĻŋāĻĄāĻžāĻŽ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āĻ•āĻžāϰāϪ⧇ āϏ⧃āĻˇā§āϟ āϝ⧌āύāĻŦāĻžāĻšāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Etiology: Infection with T. pallidum.

Pathophysiology: Organism dissemination and host inflammatory responses produce staged systemic manifestations.

āĻŦāĻžāĻ‚āϞāĻž: āĻœā§€āĻŦāĻžāϪ⧁ āĻļāϰ⧀āϰ⧇ āĻ›ā§œāĻŋā§Ÿā§‡ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻ…āĻ™ā§āϗ⧇ āĻĒā§āϰāĻĻāĻžāĻš āϏ⧃āĻˇā§āϟāĻŋ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Clinical features: Primary chancre, lymphadenopathy, secondary rash, mucosal lesions and other stage-dependent findings.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āĻĒāĻ°ā§āϝāĻžā§Ÿā§‡ āϘāĻž āĻāĻŦāĻ‚ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĒāĻ°ā§āϝāĻžā§Ÿā§‡ āĻ°â€ā§āϝāĻžāĻļāϏāĻš āύāĻžāύāĻž āωāĻĒāϏāĻ°ā§āĻ— āĻĻ⧇āĻ–āĻž āĻĻāĻŋāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Important distinction: Primary and secondary manifestations can overlap; the presence of both complaints does not confirm either stage.

āĻŦāĻžāĻ‚āϞāĻž: āϘāĻž āĻ“ āĻ°â€ā§āϝāĻžāĻļ āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻĨāĻžāĻ•āϞ⧇āĻ“ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āφāϗ⧇ āϰ⧋āϗ⧇āϰ āĻĒāĻ°ā§āϝāĻžā§Ÿ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Patient-specific diagnostic relevance: High.

Confidence: 0.70 for this differential.

6.3 Genital Herpes — āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āĻšāĻžāϰāĻĒāĻŋāϏ

Definition: Genital infection caused by herpes simplex virus, usually HSV-1 or HSV-2.

āĻŦāĻžāĻ‚āϞāĻž: HSV-1 āĻ…āĻĨāĻŦāĻž HSV-2 āĻ­āĻžāχāϰāĻžāϏ⧇āϰ āĻ•āĻžāϰāϪ⧇ āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Pathophysiology: Viral replication in epithelial cells produces vesicles and ulceration; latency can develop in sensory ganglia.

āĻŦāĻžāĻ‚āϞāĻž: āĻ­āĻžāχāϰāĻžāϏ āĻ¤ā§āĻŦāϕ⧇āϰ āϕ⧋āώ⧇ āĻŦāĻ‚āĻļāĻŦ⧃āĻĻā§āϧāĻŋ āĻ•āϰ⧇ āĻĢā§‹āϏāĻ•āĻž āĻ“ āϘāĻž āϤ⧈āϰāĻŋ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇ āĻāĻŦāĻ‚ āĻ¸ā§āύāĻžā§Ÿā§āϤ⧇ āϏ⧁āĻĒā§āϤ āĻ…āĻŦāĻ¸ā§āĻĨāĻžā§Ÿ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Clinical features: Pain, vesicles, ulcers, burning, dysuria and recurrence.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻĨāĻž, āĻĢā§‹āϏāĻ•āĻž, āϘāĻž, āĻœā§āĻŦāĻžāϞāĻžāĻĒā§‹ā§œāĻž, āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇ āĻ…āĻ¸ā§āĻŦāĻ¸ā§āϤāĻŋ āĻŦāĻž āĻŦāĻžāϰāĻŦāĻžāϰ āϘāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Patient-specific limitation: Vesicles, ulcer pain and recurrence are not documented.

Confidence: 0.65 as a possible cause.

6.4 Secondary Bacterial Infection — āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ

Definition: Bacterial infection occurring within damaged or diseased skin.

āĻŦāĻžāĻ‚āϞāĻž: āφāϗ⧇ āĻĨ⧇āϕ⧇ āĻ•ā§āώāϤāĻŋāĻ—ā§āϰāĻ¸ā§āϤ āĻ¤ā§āĻŦāĻ• āĻŦāĻž āϘāĻžā§Ÿā§‡āϰ āĻ“āĻĒāϰ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Possible organisms: Staphylococcus aureus and Streptococcus pyogenes in relevant superficial skin infections.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāϛ⧁ āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻ¸ā§āĻŸā§āϝāĻžāĻĢāĻžāχāϞ⧋āĻ•āĻ•ā§āĻ•āĻžāϏ āĻ“ āĻ¸ā§āĻŸā§āϰ⧇āĻĒāĻŸā§‹āĻ•āĻ•ā§āĻ•āĻžāϏ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻž āϜ⧜āĻŋāϤ āĻĨāĻžāϕ⧇āĨ¤

Clinical features: Purulence, surrounding erythema, warmth, crusting or spreading inflammation.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒ⧁āρāϜ, āϞāĻžāϞāĻ­āĻžāĻŦ, āĻ—āϰāĻŽ āĻ…āύ⧁āĻ­ā§‚āϤāĻŋ, āĻ–ā§‹āϏāĻž āĻŦāĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ›ā§œāĻŋā§Ÿā§‡ āĻĒ⧜āĻžāĨ¤

Patient-specific interpretation: Mupirocin and linezolid suggest possible concern for bacterial infection, but this does not prove bacterial involvement.

āĻŦāĻžāĻ‚āϞāĻž: āĻ“āώ⧁āϧ āĻĻ⧇āϖ⧇ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻ¨ā§āĻĻ⧇āĻš āĻŦā§‹āĻāĻž āϗ⧇āϞ⧇āĻ“ āϤāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

Confidence: 0.50 for this patient.


🟧 SECTION 7. DIFFERENTIAL DIAGNOSIS

RankDifferential DiagnosisSupporting EvidenceMissing EvidenceAssessment Confidence
1Syphilis — āϏāĻŋāĻĢāĻŋāϞāĻŋāϏGenital ulcer + rash + VDRL orderedSerology, lesion morphology, exposure history0.70
2Genital HSV Infection — āĻœā§‡āύāĻŋāϟāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏGenital ulcerPain, vesicles, recurrence, PCR0.65
3Secondary Bacterial Infection — āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖAntibiotic prescriptionNo documented pus, cellulitis or culture0.50
4Fixed Drug Eruption — āĻ“āώ⧁āϧāϜāύāĻŋāϤ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ¸ā§āĻĨāĻžāύ⧇āϰ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻžGenital erosion and rash can coexistDrug exposure history absent0.40
5Candidal/Erosive Balanitis — āĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āĻŦā§āϝāĻžāϞāĻžāύāĻžāχāϟāĻŋāϏGenital skin lesion possibleLocal morphology unknown0.35
6Chancroid — āĻļā§āϝāĻžāĻ‚āĻ•ā§āĻ°ā§Ÿā§‡āĻĄGenital ulcer possibleTypical painful ulcer/tender nodes not documented0.30
7Genital Malignancy — āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āĻ•ā§āϝāĻžāύāϏāĻžāϰConsider in persistent atypical ulcerNo suspicious morphology or duration documented0.30
8Behçet Disease — āĻŦ⧇āĻšāϏ⧇āϟ āϰ⧋āĻ—Genital ulcer possibleRecurrent oral ulcers and other findings absent0.20

Interpretation: These scores express confidence in considering a diagnosis, not the patient’s statistical probability of having it.

āĻŦāĻžāĻ‚āϞāĻž: āĻāϗ⧁āϞ⧋ āϰ⧋āĻ— āĻšāĻ“ā§ŸāĻžāϰ āĻļāϤāĻžāĻ‚āĻļ āύ⧟; āϕ⧋āύ āϰ⧋āĻ—āϟāĻŋ āĻ•āϤāϟāĻž āϗ⧁āϰ⧁āĻ¤ā§āĻŦ āĻĻāĻŋā§Ÿā§‡ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāĻž āωāϚāĻŋāϤ āϤāĻžāϰ āĻāĻ•āϟāĻŋ āϤāĻĨā§āϝāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤


🟩 SECTION 8. FINAL WORKING CLINICAL DIAGNOSIS

FINAL PROVISIONAL / WORKING Dx

Undifferentiated Genital Ulcer Disease (GUD) with Associated Cutaneous Rash and Generalized Weakness — Rule Out Syphilis and Genital Herpes Simplex Virus Infection; Consider Secondary Superficial Bacterial Infection.

āĻŦāĻžāĻ‚āϞāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āĻ•āĻžāϰāĻŖ āĻ…āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āϘāĻž, āϏāĻ™ā§āϗ⧇ āĻ¤ā§āĻŦāϕ⧇ āĻ°â€ā§āϝāĻžāĻļ āĻ“ āϏāĻžāĻ°ā§āĻŦāĻŋāĻ• āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻžāĨ¤ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻāĻŦāĻ‚ āĻœā§‡āύāĻŋāϟāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻ•ā§āώāϤ⧇ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻĨāĻžāĻ•āĻžāĻ“ āϏāĻŽā§āĻ­āĻŦāĨ¤

Confidence in symptom-based working diagnosis: 0.99.

Confidence in syphilis as a differential: 0.70.

Confidence in genital herpes as a differential: 0.65.

Confidence in secondary bacterial infection: 0.50.

Definitive etiological diagnosis: Not established.

Prescription-Ready Short Dx

Dx: Genital Ulcer Disease (Etiology Undetermined) with Skin Rash — R/O Syphilis / Genital HSV; ?Secondary Bacterial Infection.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āĻ“ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ°â€ā§āϝāĻžāĻļ; āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ“ āĻšāĻžāϰāĻĒāĻŋāϏ āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤


🟧 SECTION 9. ORIGINAL PRESCRIPTION DRUG SUMMARY

Table 1 — Original Drugs and Clinical Purpose

No.Original BrandGenericMedEx Therapeutic ClassPossible Clinical Purpose
1Linzolid 600 mgLinezolidMacrolides — MedEx label, pharmacologically incorrectSuspected bacterial infection
2Fenadin 120 mgFexofenadineAnti-histamineAllergy/rash-associated itching
3DDR 30 mgDexlansoprazoleProton Pump InhibitorAcid suppression
4Coralcin-DCoral calcium + Vitamin D3Specific mineral & vitamin combined preparationsCalcium/vitamin supplementation
5Muron 2%MupirocinTopical Antibiotic preparationsSuperficial bacterial skin infection
6SupravitMultivitamin [Adult preparation]Specific combined vitamin preparationsVitamin supplementation

Confidence: 0.98 for brand identification and verified generic information.

Original Dosing Transcription

The prescription appears to contain the following instructions:

  • Linzolid 600 mg: Approximately 1+0+1; duration appears 20 days.
  • Fenadin 120 mg: Appears once daily; duration handwriting is unclear.
  • DDR 30 mg: Appears once daily with a fasting instruction; exact duration unclear.
  • Coralcin-D: Appears once daily; duration uncertain.
  • Muron 2%: Topical application; frequency and duration require confirmation, although the duration appears close to 20 days.
  • Supravit: Appears once daily; duration uncertain.

Clinical safety note: These are transcriptions of a handwritten prescription, not independently validated dosing instructions. Illegible directions must be confirmed with the original prescriber or dispensing pharmacist.

Transcription confidence: 0.55–0.85 depending on the instruction.


🟧 SECTION 10. COMPLETE 17-PARAMETER MEDICINE REVIEW

🟩 MEDICINE 1 — LINZOLID 600 MG

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Linezolid — āϞāĻžāχāύāĻœā§‹āϞāĻŋāĻĄāĨ¤

An antibacterial agent used against selected Gram-positive organisms.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ—ā§āϰāĻžāĻŽ-āĻĒāϜāĻŋāϟāĻŋāĻ­ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āĻŦāĻŋāϰ⧁āĻĻā§āϧ⧇ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•āĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Linzolid 600 mg Tablet — Incepta Pharmaceuticals Ltd.

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Arlin, Linez, Linexil, Lizolix, Lizox, Linbid and other linezolid brands.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤ strength āĻ“ formulation āĻ…āĻŦāĻļā§āϝāχ āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āύāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

4. MedEx Therapeutic Class — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻļā§āϰ⧇āĻŖāĻŋ

MedEx displays: Macrolides.

Important correction: This classification is inconsistent with established pharmacology.

āĻŦāĻžāĻ‚āϞāĻž: MedEx-āĻ Macrolides āϞ⧇āĻ–āĻž āĻĨāĻžāĻ•āϞ⧇āĻ“ Linezolid āφāϏāϞ⧇ Macrolide āύ⧟āĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Oxazolidinone antibiotic — āĻ…āĻ•ā§āϏāĻžāĻœā§‹āϞāĻŋāĻĄāĻŋāύ⧋āύ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•āĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Treatment of selected Gram-positive bacterial infections, including certain resistant organisms.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āĻŦāĻŋāĻļ⧇āώāϤ āĻ•āĻŋāϛ⧁ āĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

7. Why Doctor Prescribed It — āĻāχ āϰ⧋āĻ—ā§€āϕ⧇ āϕ⧇āύ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ?

The physician may have suspected bacterial infection involving the genital lesion or skin.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āĻ…āĻĨāĻŦāĻž āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϏāĻ¨ā§āĻĻ⧇āĻš āĻ•āϰ⧇ āĻĻāĻŋā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤

However: No definitive bacterial diagnosis is documented.

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Diarrhoea, nausea, headache, thrombocytopenia, anaemia, myelosuppression, peripheral neuropathy, optic neuropathy and serotonin syndrome.

āĻŦāĻžāĻ‚āϞāĻž: āĻĄāĻžā§ŸāϰāĻŋ⧟āĻž, āĻŦāĻŽāĻŋāĻ­āĻžāĻŦ, āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āĻĒā§āϞ⧇āϟāϞ⧇āϟ āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻž, āϰāĻ•ā§āϤāĻ¸ā§āĻŦāĻ˛ā§āĻĒāϤāĻž, āĻ…āĻ¸ā§āĻĨāĻŋāĻŽāĻœā§āϜāĻžāϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻž, āĻ¸ā§āύāĻžā§Ÿā§āϰ āĻ•ā§āώāϤāĻŋ āĻāĻŦāĻ‚ āĻ•āĻŋāϛ⧁ āĻ“āώ⧁āϧ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻŦāĻŋāĻĒāĻœā§āϜāύāĻ• āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ MedEx āϞāĻŋāĻ‚āĻ•

Linzolid 600 mg — MedEx Bangladesh

10. Unit Price, Strip Price and Other Forms — āĻĻāĻžāĻŽ āĻ“ āϧāϰāύ

Unit price: ā§ŗ85.00
Strip price: ā§ŗ850.00 per 10-tablet strip.

Other forms: 400 mg tablet, 100 mg/5 mL oral suspension and 2 mg/mL IV infusion.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāϤāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ ā§Žā§Ģ āϟāĻžāĻ•āĻž āĻāĻŦāĻ‚ ā§§ā§ĻāϟāĻŋāϰ āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ ā§Žā§Ģā§Ļ āϟāĻžāĻ•āĻžāĨ¤

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and preventing formation of the initiation complex.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āĻĒā§āϰ⧋āϟāĻŋāύ āϤ⧈āϰāĻŋāϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āϧāĻžāĻĒ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧇ āĻœā§€āĻŦāĻžāϪ⧁āϰ āĻŦ⧃āĻĻā§āϧāĻŋ āĻĒā§āϰāϤāĻŋāϰ⧋āϧ āĻ•āϰ⧇āĨ¤

12. Drug Indications — āϕ⧋āύ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿ?

Selected pneumonia, complicated skin and soft-tissue infections, resistant Gram-positive infections and VRE infection.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āύāĻŋāωāĻŽā§‹āύāĻŋ⧟āĻž, āϜāϟāĻŋāϞ āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻāĻŦāĻ‚ āĻ•āĻŋāϛ⧁ āĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§ŸāĨ¤

13. Drug Interactions + Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

Important interactions include MAO inhibitors, serotonergic antidepressants, certain opioids and sympathomimetic medicines.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāϛ⧁ antidepressant, MAOI, opioid āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ“āώ⧁āϧ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻŦāĻŋāĻĒāĻœā§āϜāύāĻ• āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Contraindications include hypersensitivity and use with MAO inhibitors within the contraindicated interval.

āĻŦāĻžāĻ‚āϞāĻž: Linezolid-āĻ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻ…āĻĨāĻŦāĻž āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ MAOI āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Weekly CBC monitoring is recommended during linezolid treatment, especially when therapy exceeds two weeks.

āĻŦāĻžāĻ‚āϞāĻž: Linezolid āĻŦā§āϝāĻŦāĻšāĻžāϰāĻ•āĻžāϞ⧇ āύāĻŋ⧟āĻŽāĻŋāϤ CBC āĻĒāϰ⧀āĻ•ā§āώāĻž āϜāϰ⧁āϰāĻŋ, āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇ āĻĻ⧁āχ āϏāĻĒā§āϤāĻžāĻšā§‡āϰ āĻŦ⧇āĻļāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§ŸāĨ¤

Check for thrombocytopenia, anaemia, neuropathy, visual symptoms and serotonin syndrome.

āĻŦāĻžāĻ‚āϞāĻž: āϰāĻ•ā§āϤāĻ•āĻŖāĻŋāĻ•āĻž, āĻĒā§āϞ⧇āϟāϞ⧇āϟ, āĻ¸ā§āύāĻžā§Ÿā§ āĻ“ āĻĻ⧃āĻˇā§āϟāĻŋāĻļāĻ•ā§āϤāĻŋāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϏāĻŽāĻ¸ā§āϝāĻž āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āϏ⧇āĻŦāύāĻŦāĻŋāϧāĻŋ

For selected serious infections, an adult regimen is 600 mg every 12 hours; duration depends on the indication.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻĒā§āϰāĻžāĻĒā§āϤāĻŦ⧟āĻ¸ā§āĻ•āĻĻ⧇āϰ ⧧⧍ āϘāĻŖā§āϟāĻž āĻ…āĻ¨ā§āϤāϰ ā§Ŧā§Ļā§Ļ āĻŽāĻŋ.āĻ—ā§āϰāĻž. āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿ, āϤāĻŦ⧇ āϰ⧋āĻ— āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŽā§‡ā§ŸāĻžāĻĻ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāĻŋāϤ āĻšā§ŸāĨ¤

Patient-specific concern: The handwritten regimen appears to involve a prolonged course. Its appropriateness cannot be confirmed without the bacterial diagnosis.

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Use during pregnancy only when justified by individual benefit–risk assessment; linezolid enters breast milk.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ“ āĻā§āρāĻ•āĻŋ āĻŦāĻŋāϚāĻžāϰ āĻ•āϰ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϤ⧇ āĻšā§ŸāĨ¤ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻ⧁āĻ—ā§āϧ⧇ āĻ“āώ⧁āϧ āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Patient relevance: The patient is male; this information is included for pharmacological completeness.

17. Other Combinations — āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

MedEx lists alternative strengths and dosage forms. A relevant fixed-dose linezolid combination is not established on the reviewed brand page.

āĻŦāĻžāĻ‚āϞāĻž: ā§Ēā§Ļā§Ļ āĻŽāĻŋ.āĻ—ā§āϰāĻž. āĻŸā§āϝāĻžāĻŦāϞ⧇āϟāϏāĻš āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ strength āĻ“ formulation āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§Ÿ; āĻāϗ⧁āϞ⧋ āφāϞāĻžāĻĻāĻž combination drug āύ⧟āĨ¤

🟧 Clinical Safety Verdict

Potentially inappropriate without clear bacterial indication.

Linezolid does not provide recommended definitive treatment for syphilis or genital herpes.

āĻŦāĻžāĻ‚āϞāĻž: āĻļ⧁āϧ⧁ āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āĻ“ āĻ°â€ā§āϝāĻžāĻļ āĻĨāĻžāĻ•āĻžāϰ āĻ•āĻžāϰāϪ⧇ āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ Linezolid āĻŦā§āϝāĻŦāĻšāĻžāϰāϕ⧇ āϝāĻĨāĻžāϝāĻĨ āĻŦāϞāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āϝāĻžāϚāĻžāχ āϜāϰ⧁āϰāĻŋāĨ¤

Pharmacology confidence: 0.99.
Patient-specific indication confidence: 0.45.

Source:


🟩 MEDICINE 2 — FENADIN 120 MG

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Fexofenadine Hydrochloride — āĻĢ⧇āĻ•ā§āϏ⧋āĻĢ⧇āύāĻžāĻĄāĻŋāύ āĻšāĻžāχāĻĄā§āϰ⧋āĻ•ā§āϞ⧋āϰāĻžāχāĻĄāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Fenadin 120 mg Tablet — Renata PLC.

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Other fexofenadine brands are available in Bangladesh; equivalent products should be selected from the MedEx alternate-brand listing after verifying strength.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤ ⧧⧍ā§Ļ āĻŽāĻŋ.āĻ—ā§āϰāĻž. strength āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

4. MedEx Therapeutic Class — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āĻļā§āϰ⧇āĻŖāĻŋ

Anti-histamine — āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Second-generation peripheral H1-antihistamine — āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒā§āϰāϜāĻ¨ā§āĻŽā§‡āϰ H1 āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύāĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Relief of allergic rhinitis and urticaria-associated symptoms.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻšāĻžāρāϚāĻŋ, āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋ āĻĒ⧜āĻž, āϚāĻžāĻ•āĻž āĻ“āĻ āĻž āĻ“ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻ•āĻŽāĻžāϤ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§ŸāĨ¤

7. Why Doctor Prescribed It — āĻāχ āϰ⧋āĻ—ā§€āϕ⧇ āϕ⧇āύ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ?

Possibly for itching or allergic symptoms associated with skin rash.

āĻŦāĻžāĻ‚āϞāĻž: āĻ°â€ā§āϝāĻžāĻļ⧇āϰ āϏāĻ™ā§āϗ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻŦāĻž āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āĻĨāĻžāĻ•āϞ⧇ āĻ•āĻŽāĻžāύ⧋āϰ āϜāĻ¨ā§āϝ āĻĻāĻŋā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤

Limitation: Itching was not explicitly documented.

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Headache, nausea, dizziness and occasional drowsiness.

āĻŦāĻžāĻ‚āϞāĻž: āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āĻŦāĻŽāĻŋāĻ­āĻžāĻŦ, āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž āĻ“ āĻ•āĻ–āύ⧋ āϘ⧁āĻŽāϘ⧁āĻŽ āĻ­āĻžāĻŦāĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻ‚āĻ•

Fenadin 120 mg — MedEx Bangladesh

10. Unit Price, Strip Price and Other Forms — āĻĻāĻžāĻŽ āĻ“ āϧāϰāύ

Unit price: ā§ŗ9.00
Strip price: ā§ŗ90.00.

Other forms: 60 mg tablet, 180 mg tablet, 30 mg dispersible tablet and oral suspension.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāϤāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ ⧝ āϟāĻžāĻ•āĻž; ā§§ā§ĻāϟāĻŋāϰ āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ ā§¯ā§Ļ āϟāĻžāĻ•āĻžāĨ¤

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Blocks peripheral histamine H1-receptor activity.

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύ⧇āϰ āĻĒā§āϰāĻ­āĻžāĻŦ āĻ•āĻŽāĻŋā§Ÿā§‡ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻ“ āϚ⧁āϞāĻ•āĻžāύāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āωāĻĒāĻļāĻŽ āĻ•āϰ⧇āĨ¤

12. Drug Indications — āϕ⧋āύ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿ?

Allergic rhinitis and urticaria.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĻ• āϰāĻžāχāύāĻžāχāϟāĻŋāϏ āĻ“ āφāĻ°ā§āϟāĻŋāϕ⧇āϰāĻŋ⧟āĻžāĨ¤

13. Drug Interactions + Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

Aluminium/magnesium-containing antacids may reduce absorption; fruit juices can reduce bioavailability. Avoid in hypersensitivity.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāϛ⧁ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻžāϏāĻŋāĻĄ āĻ“ āĻĢāϞ⧇āϰ āϰāϏ āĻ“āώ⧁āϧ⧇āϰ āĻļā§‹āώāĻŖ āĻ•āĻŽāĻžāϤ⧇ āĻĒāĻžāϰ⧇; āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώāĻŋāĻĻā§āϧāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Renal impairment may require a lower starting dose.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāĻĄāύāĻŋāϰ āϏāĻŽāĻ¸ā§āϝāĻžā§Ÿ āĻ•āĻŽ āĻŽāĻžāĻ¤ā§āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž

Adults may receive 120 mg once daily for an appropriate indication.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāĻžāĻĒā§āϤāĻŦ⧟āĻ¸ā§āĻ•āĻĻ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āϰ⧋āϗ⧇ āĻĻ⧈āύāĻŋāĻ• āĻāĻ•āĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Individual benefit–risk assessment is needed.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϏāϤāĻ°ā§āĻ• āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

Other fexofenadine preparations and strengths are available; an exact fixed combination should not be assumed from the brand name.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ strength āĻ“ formulation āĻ°ā§Ÿā§‡āϛ⧇; āϏ⧇āϗ⧁āϞ⧋ āĻāĻ•āχ āϧāϰāύ⧇āϰ combination āύ⧟āĨ¤

🟧 Clinical Verdict

Appropriate for relevant allergic symptoms, but not a treatment for an infectious genital ulcer.

āĻŦāĻžāĻ‚āϞāĻž: āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻ•āĻŽāĻžāϤ⧇ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ āĻšāϤ⧇ āĻĒāĻžāϰ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ āĻ•āĻŋāĻ‚āĻŦāĻž āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻžā§Ÿā§‡āϰ āĻŽā§‚āϞ āĻ•āĻžāϰāĻŖ āϏāĻžāϰāĻžā§Ÿ āύāĻžāĨ¤

Drug confidence: 0.99.
Patient-specific indication confidence: 0.60.

Source:


🟩 MEDICINE 3 — DDR 30 MG

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Dexlansoprazole — āĻĄā§‡āĻ•ā§āϏāĻ˛ā§āϝāĻžāύāϏ⧋āĻĒā§āϰāĻžāϜāϞāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

DDR 30 mg EC Capsule — ACME Laboratories Ltd.

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Aslan-D, Canalia, Delanix, Delanzo, Delpraz and other dexlansoprazole brands.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ āĻ…āĻ¨ā§āϝ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

4. MedEx Therapeutic Class — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āĻļā§āϰ⧇āĻŖāĻŋ

Proton Pump Inhibitor — āĻĒā§āϰ⧋āϟāύ āĻĒāĻžāĻŽā§āĻĒ āχāύāĻšāĻŋāĻŦāĻŋāϟāϰāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Gastric acid secretion inhibitor — āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āĻ…ā§āϝāĻžāϏāĻŋāĻĄ āύāĻŋāσāϏāϰāĻŖāϰ⧋āϧ⧀ āĻ“āώ⧁āϧāĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Treatment of GERD and erosive oesophagitis.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—ā§āϝāĻžāĻ¸ā§āĻŸā§āϰ⧋āχāϏ⧋āĻĢ⧇āϜāĻŋ⧟āĻžāϞ āϰāĻŋāĻĢā§āϞāĻžāĻ•ā§āϏ āĻ“ āĻ–āĻžāĻĻā§āϝāύāĻžāϞāĻŋāϰ āĻ…ā§āϝāĻžāϏāĻŋāĻĄāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§‡ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤

7. Why Doctor Prescribed It — āϕ⧇āύ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ?

Possibly for an undocumented acid-related complaint or empirical gastric acid suppression.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āĻ…ā§āϝāĻžāϏāĻŋāĻĄāϜāύāĻŋāϤ āϕ⧋āύ⧋ āϏāĻŽāĻ¸ā§āϝāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Important: No acid-related complaint is written in C/C.

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Diarrhoea, nausea, abdominal discomfort and flatulence.

āĻŦāĻžāĻ‚āϞāĻž: āĻĄāĻžā§ŸāϰāĻŋ⧟āĻž, āĻŦāĻŽāĻŋāĻ­āĻžāĻŦ, āĻĒ⧇āĻŸā§‡āϰ āĻ…āĻ¸ā§āĻŦāĻ¸ā§āϤāĻŋ āĻ“ āĻ—ā§āϝāĻžāϏāĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻ‚āĻ•

DDR 30 mg — MedEx Bangladesh

10. Unit Price, Strip Price and Other Forms — āĻĻāĻžāĻŽ āĻ“ āϧāϰāύ

Unit price: ā§ŗ11.50
Strip price: ā§ŗ115.00.

Other strength: DDR 60 mg.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāϤāĻŋ āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ ā§§ā§§.ā§Ģā§Ļ āϟāĻžāĻ•āĻž āĻāĻŦāĻ‚ ā§§ā§ĻāϟāĻŋāϰ āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ ā§§ā§§ā§Ģ āϟāĻžāĻ•āĻžāĨ¤

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Inhibits gastric Hâē/Kâē-ATPase in parietal cells.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āĻ…ā§āϝāĻžāϏāĻŋāĻĄ āĻ‰ā§ŽāĻĒāĻžāĻĻāύ⧇āϰ āĻĒā§āϰāϧāĻžāύ āĻāύāϜāĻžāχāĻŽāϕ⧇ āĻŦāĻžāϧāĻž āĻĻā§‡ā§ŸāĨ¤

12. Drug Indications — āϕ⧋āύ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿ?

GERD, erosive oesophagitis and maintenance of healed erosive oesophagitis.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϏāĻŋāĻĄ āϰāĻŋāĻĢā§āϞāĻžāĻ•ā§āϏ, āĻŦ⧁āĻ•āĻœā§āĻŦāĻžāϞāĻž āĻāĻŦāĻ‚ āĻ–āĻžāĻĻā§āϝāύāĻžāϞāĻŋāϰ āĻ…ā§āϝāĻžāϏāĻŋāĻĄāϜāύāĻŋāϤ āĻ•ā§āώāϤāĨ¤

13. Drug Interactions + Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

Interactions may occur with certain acid-dependent medicines, some antiretrovirals, warfarin and high-dose methotrexate. Avoid in hypersensitivity.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāϛ⧁ āĻ“āώ⧁āϧ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āĻŦāĻž āϰāĻ•ā§āϤ⧇āϰ āĻŽāĻžāĻ¤ā§āϰāĻžā§Ÿ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āϘāϟāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Avoid unnecessary prolonged PPI use. Reassess long-term indication.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ›āĻžā§œāĻž āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āĻ—ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž

30 mg once daily is an established regimen for selected acid-related indications.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…ā§āϝāĻžāϏāĻŋāĻĄāϜāύāĻŋāϤ āϰ⧋āϗ⧇ āĻĻ⧈āύāĻŋāĻ• āĻāĻ•āĻŦāĻžāϰ ā§Šā§Ļ āĻŽāĻŋ.āĻ—ā§āϰāĻž. āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāĨ¤

Dexlansoprazole can generally be administered with or without food.

āĻŦāĻžāĻ‚āϞāĻž: āĻāχ āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻŦāĻž āĻ›āĻžā§œāĻžāĻ“ āϏ⧇āĻŦāύ āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Use after clinical benefit–risk evaluation.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ“ āĻā§āρāĻ•āĻŋ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

Other strengths and alternative formulations exist; a fixed-dose combination is not established on the reviewed DDR page.

āĻŦāĻžāĻ‚āϞāĻž: ā§Šā§Ļ āĻ“ ā§Ŧā§Ļ āĻŽāĻŋ.āĻ—ā§āϰāĻž. strength āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

🟧 Clinical Verdict

No clear documented indication.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻŽā§‚āϞ āĻ…āĻ­āĻŋāϝ⧋āϗ⧇ āĻŦ⧁āĻ•āĻœā§āĻŦāĻžāϞāĻž āĻŦāĻž āĻ…ā§āϝāĻžāϏāĻŋāĻĄāϜāύāĻŋāϤ āϏāĻŽāĻ¸ā§āϝāĻž āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤ āϤāĻžāχ DDR āĻĻ⧇āĻ“ā§ŸāĻžāϰ āϏ⧁āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ•āĻžāϰāĻŖ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

Drug confidence: 0.99.
Patient-specific indication confidence: 0.35.

Source:


🟩 MEDICINE 4 — CORALCIN-D

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Coral Calcium + Vitamin D3 — āϕ⧋āϰāĻžāϞ āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻ“ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻĄāĻŋā§ŠāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Coralcin-D 500 mg + 200 IU Tablet — Renata PLC.

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Other calcium carbonate/coral calcium plus vitamin D preparations are available.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āχ āϧāϰāύ⧇āϰ āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻ“ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻĄāĻŋ āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§Ÿ, āϤāĻŦ⧇ elemental calcium-āĻāϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āύāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

4. MedEx Therapeutic Class — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āĻļā§āϰ⧇āĻŖāĻŋ

Specific mineral & vitamin combined preparations.

āĻŦāĻžāĻ‚āϞāĻž: āĻ–āύāĻŋāϜ āĻ“ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ⧇āϰ āϏāĻŽāĻ¨ā§āĻŦāĻŋāϤ āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Calcium supplement + Cholecalciferol — āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻ“ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻĄāĻŋ āϏāĻŽā§āĻĒā§‚āϰāĻ•āĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Prevention or management of calcium/vitamin D inadequacy and selected bone disorders.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻ“ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻĄāĻŋāϰ āϘāĻžāϟāϤāĻŋ āĻāĻŦāĻ‚ āĻ•āĻŋāϛ⧁ āĻšāĻžā§œā§‡āϰ āϰ⧋āϗ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤

7. Why Doctor Prescribed It — āϕ⧇āύ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ?

Possibly for generalized weakness or presumed nutritional inadequacy.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻŦāĻž āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒ⧁āĻˇā§āϟāĻŋāϰ āϘāĻžāϟāϤāĻŋāϰ āϜāĻ¨ā§āϝ āĻĻāĻŋā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤

Limitation: Deficiency has not been demonstrated.

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Constipation, gastrointestinal discomfort and hypercalcaemia with excessive intake.

āĻŦāĻžāĻ‚āϞāĻž: āϕ⧋āĻˇā§āĻ āĻ•āĻžāĻ āĻŋāĻ¨ā§āϝ, āĻĒ⧇āĻŸā§‡āϰ āĻ…āĻ¸ā§āĻŦāĻ¸ā§āϤāĻŋ āĻāĻŦāĻ‚ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻ—ā§āϰāĻšāϪ⧇ āϰāĻ•ā§āϤ⧇ āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻŦā§‡ā§œā§‡ āϝāĻžāĻ“ā§ŸāĻžāĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻ‚āĻ•

Coralcin-D — MedEx Bangladesh

10. Unit Price, Strip Price and Other Forms — āĻĻāĻžāĻŽ āĻ“ āϧāϰāύ

Unit price: ā§ŗ11.50
Strip price: ā§ŗ115.00.

Composition: Calcium carbonate 1250 mg, equivalent to elemental calcium 500 mg, with vitamin D3 200 IU.

Other forms: 500 mg + 400 IU and 600 mg + 400 IU preparations.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāϤāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ ā§§ā§§.ā§Ģā§Ļ āϟāĻžāĻ•āĻž; ā§§ā§ĻāϟāĻŋāϰ āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ ā§§ā§§ā§Ģ āϟāĻžāĻ•āĻžāĨ¤

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Calcium contributes to mineral homeostasis and bone mineralisation. Vitamin D improves intestinal calcium absorption.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻšāĻžā§œā§‡āϰ āĻ–āύāĻŋāϜ āωāĻĒāĻžāĻĻāĻžāύ āϏāϰāĻŦāϰāĻžāĻš āĻ•āϰ⧇ āĻāĻŦāĻ‚ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻĄāĻŋ āĻļāϰ⧀āϰ⧇ āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻļā§‹āώāϪ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

12. Drug Indications — āϕ⧋āύ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿ?

Calcium deficiency, selected osteoporosis management, osteomalacia and other deficiency-related conditions.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽā§‡āϰ āϘāĻžāϟāϤāĻŋ, āĻ…āĻ¸ā§āϟāĻŋāĻ“āĻĒā§‹āϰ⧋āϏāĻŋāϏ āĻ“ āĻ…āĻ¸ā§āϟāĻŋāĻ“āĻŽā§āϝāĻžāϞāĻžāϏāĻŋ⧟āĻžāϏāĻš āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…āĻŦāĻ¸ā§āĻĨāĻžā§ŸāĨ¤

13. Drug Interactions + Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

Interactions include reduced absorption of certain antibiotics and levothyroxine. Use cautiously with thiazides and digoxin. Contraindications include hypercalcaemia.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāϛ⧁ āĻ“āώ⧁āϧ⧇āϰ āĻļā§‹āώāĻŖ āĻ•āĻŽāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āϰāĻ•ā§āϤ⧇ āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻŦ⧇āĻļāĻŋ āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Assess kidney-stone history, renal function and total calcium/vitamin D intake.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāĻĄāύāĻŋāϤ⧇ āĻĒāĻžāĻĨāϰ, āĻ•āĻŋāĻĄāύāĻŋāϰ āϰ⧋āĻ— āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝ āϏāĻžāĻĒā§āϞāĻŋāĻŽā§‡āĻ¨ā§āϟ āĻĨ⧇āϕ⧇ āĻ•āϤ āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āύ⧇āĻ“ā§ŸāĻž āĻšāĻšā§āϛ⧇ āϤāĻž āϝāĻžāϚāĻžāχ āϜāϰ⧁āϰāĻŋāĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž

Dosage depends on indication and dietary intake. Calcium carbonate preparations are generally taken with food.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ— āĻ“ āĻ–āĻžāĻĻā§āϝāĻžāĻ­ā§āϝāĻžāϏ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŽāĻžāĻ¤ā§āϰāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āĻšā§Ÿ; āϏāĻžāϧāĻžāϰāĻŖāϤ āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āϏāĻ™ā§āϗ⧇ āύ⧇āĻ“ā§ŸāĻž āĻšā§ŸāĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

May be used for an established nutritional indication with appropriate dosing.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āĻŽāĻžāĻ¤ā§āϰāĻžā§Ÿ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

500/400 IU and 600/400 IU strengths are available.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽ āĻ“ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻĄāĻŋāϰ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ strength āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

🟧 Clinical Verdict

Supplementation is not supported by documented deficiency in this prescription.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻĨāĻžāĻ•āϞ⧇āχ āĻ•ā§āϝāĻžāϞāϏāĻŋ⧟āĻžāĻŽā§‡āϰ āϘāĻžāϟāϤāĻŋ āφāĻ›ā§‡â€”āĻāĻŽāύ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āϏāĻ āĻŋāĻ• āύ⧟āĨ¤

Drug confidence: 0.99.
Patient-specific indication confidence: 0.35.

Source:


🟩 MEDICINE 5 — MURON 2% OINTMENT

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Mupirocin — āĻŽāĻŋāωāĻĒāĻŋāϰ⧋āϏāĻŋāύāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Muron 2% Ointment — Drug International Ltd.

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Other mupirocin 2% ointment and cream preparations are available.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ āĻ…āĻ¨ā§āϝ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āĻ“ cream formulation āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

4. MedEx Therapeutic Class — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āĻļā§āϰ⧇āĻŖāĻŋ

Topical Antibiotic preparations — āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•āĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Topical antibacterial agent — āĻ¸ā§āĻĨāĻžāĻ¨ā§€ā§Ÿ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāύāĻžāĻļāĻ• āĻ“āώ⧁āϧāĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Treatment of selected superficial bacterial skin infections.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āωāĻĒāϰāĻŋāĻ­āĻžāϗ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤

7. Why Doctor Prescribed It — āϕ⧇āύ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ?

Possibly for bacterial involvement in the genital ulcer.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻžā§Ÿā§‡ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžā§Ÿ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ āĻŦāϞ⧇ āϧāĻžāϰāĻŖāĻž āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤

Limitation: No pus, discharge or bacterial diagnosis is documented.

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Burning, stinging, erythema, itching and contact dermatitis.

āĻŦāĻžāĻ‚āϞāĻž: āϞāĻžāĻ—āĻžāύ⧋āϰ āϜāĻžā§ŸāĻ—āĻžā§Ÿ āĻœā§āĻŦāĻžāϞāĻžāĻĒā§‹ā§œāĻž, āϞāĻžāϞāĻ­āĻžāĻŦ, āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻŦāĻž āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻ‚āĻ•

Muron 2% Ointment — MedEx Bangladesh

10. Unit Price, Strip Price and Other Forms — āĻĻāĻžāĻŽ āĻ“ āϧāϰāύ

10 g tube price: ā§ŗ140.00.

Tablet or strip price is not applicable.

Other forms: Mupirocin cream and ointment.

āĻŦāĻžāĻ‚āϞāĻž: ā§§ā§Ļ āĻ—ā§āϰāĻžāĻŽā§‡āϰ āϟāĻŋāωāĻŦ ā§§ā§Ēā§Ļ āϟāĻžāĻ•āĻžāĨ¤

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Inhibits bacterial isoleucyl-tRNA synthetase and protein synthesis.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āĻĒā§āϰ⧋āϟāĻŋāύ āϤ⧈āϰāĻŋāϰ āϜāĻ¨ā§āϝ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻāύāϜāĻžāχāĻŽāϕ⧇ āĻŦāĻžāϧāĻž āĻĻā§‡ā§ŸāĨ¤

12. Drug Indications — āϕ⧋āύ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿ?

Impetigo, selected folliculitis and superficial bacterial skin infection.

āĻŦāĻžāĻ‚āϞāĻž: āχāĻŽāĻĒ⧇āϟāĻžāχāĻ—ā§‹, āĻ•āĻŋāϛ⧁ āĻĢāϞāĻŋāĻ•āĻŋāωāϞāĻžāχāϟāĻŋāϏ āĻāĻŦāĻ‚ āĻ¸ā§āĻĨāĻžāĻ¨ā§€ā§Ÿ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

13. Drug Interactions + Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

Major topical interactions are uncommon. Avoid in known hypersensitivity.

āĻŦāĻžāĻ‚āϞāĻž: āĻ“āώ⧁āϧ⧇āϰ āωāĻĒāĻžāĻĻāĻžāύ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Avoid inappropriate use on genital mucosal surfaces, eyes or inside the nose unless the formulation and indication are appropriate.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϭ⧇āϤāϰ⧇āϰ āĻļā§āϞ⧇āĻˇā§āĻŽāĻžāĻāĻŋāĻ˛ā§āϞāĻŋ āĻŦāĻž āĻ…āϜāĻžāύāĻž āϧāϰāύ⧇āϰ āϘāĻžā§Ÿā§‡ āύāĻŋāĻœā§‡āϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ⧇ āϞāĻžāĻ—āĻžāύ⧋ āωāϚāĻŋāϤ āύ⧟āĨ¤

Prolonged unnecessary use may promote resistant or nonsusceptible organisms.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…āĻĒā§āĻ°ā§Ÿā§‹āϜāύ⧇ āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϞ⧇ āĻœā§€āĻŦāĻžāϪ⧁āϰ āĻĒā§āϰāϤāĻŋāϰ⧋āϧāĻ•ā§āώāĻŽāϤāĻž āĻŦāĻžā§œāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž

MedEx describes application three times daily for up to 10 days in relevant skin infections.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āϏāĻ°ā§āĻŦā§‹āĻšā§āϚ ā§§ā§Ļ āĻĻāĻŋāύ āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āĻĻāĻŋāύ⧇ āϤāĻŋāύāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϤāĻĨā§āϝ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Patient-specific concern: If the prescription truly specifies 20 days, the duration requires review.

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Use after benefit–risk evaluation.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ“ āĻā§āρāĻ•āĻŋ āĻŦāĻŋāĻŦ⧇āϚāύāĻžā§Ÿ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

Different topical formulations exist; a relevant fixed combination is not established on the reviewed Muron brand page.

āĻŦāĻžāĻ‚āϞāĻž: ointment āĻ“ cream formulation āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

🟧 Clinical Verdict

Potentially appropriate for bacterial superficial infection, but not definitive treatment for syphilis or herpes.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžā§Ÿ; āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻž āĻšāĻžāϰāĻĒāĻŋāϏ āϏāĻžāϰāĻžā§Ÿ āύāĻžāĨ¤

Drug confidence: 0.99.
Patient-specific indication confidence: 0.55.

Source:


🟩 MEDICINE 6 — SUPRAVIT CAPSULE

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Multivitamin [Adult preparation] — āĻĒā§āϰāĻžāĻĒā§āϤāĻŦ⧟āĻ¸ā§āĻ•āĻĻ⧇āϰ āĻŽāĻžāĻ˛ā§āϟāĻŋāĻ­āĻŋāϟāĻžāĻŽāĻŋāύāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Supravit Capsule — Drug International Ltd.

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Other adult multivitamin preparations are available, but their exact vitamin contents may differ.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…āĻ¨ā§āϝ āĻŽāĻžāĻ˛ā§āϟāĻŋāĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϞ⧇āĻ“ āωāĻĒāĻžāĻĻāĻžāύ āĻ“ āĻŽāĻžāĻ¤ā§āϰāĻž āĻāĻ•āχ āύāĻžāĻ“ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

4. MedEx Therapeutic Class — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āĻļā§āϰ⧇āĻŖāĻŋ

Specific combined vitamin preparations — āĻāĻ•āĻžāϧāĻŋāĻ• āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ⧇āϰ āϏāĻŽāĻ¨ā§āĻŦāĻŋāϤ āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Multivitamin nutritional supplement — āĻĒ⧁āĻˇā§āϟāĻŋāĻ—āϤ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āϏāĻŽā§āĻĒā§‚āϰāĻ•āĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Prevention and management of vitamin deficiency.

āĻŦāĻžāĻ‚āϞāĻž: āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ⧇āϰ āϘāĻžāϟāϤāĻŋ āĻĒā§‚āϰāĻŖ āĻŦāĻž āĻĒā§āϰāϤāĻŋāϰ⧋āϧāĨ¤

7. Why Doctor Prescribed It — āϕ⧇āύ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ?

Possibly for weakness or nutritional support.

āĻŦāĻžāĻ‚āϞāĻž: āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻ“ āĻĒ⧁āĻˇā§āϟāĻŋāĻ—āϤ āϏāĻšāĻžā§ŸāϤāĻžāϰ āϜāĻ¨ā§āϝ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Generally well tolerated at recommended doses; gastrointestinal upset or hypersensitivity can occur.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āĻŽāĻžāĻ¤ā§āϰāĻžā§Ÿ āϏāĻžāϧāĻžāϰāĻŖāϤ āϏāĻšāĻ¨ā§€ā§ŸāĨ¤ āĻ•āĻ–āύ⧋ āĻĒ⧇āĻŸā§‡āϰ āĻ…āĻ¸ā§āĻŦāĻ¸ā§āϤāĻŋ āĻŦāĻž āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āϞāĻŋāĻ‚āĻ•

Supravit Capsule — MedEx Bangladesh

10. Unit Price, Strip Price and Composition — āĻĻāĻžāĻŽ āĻ“ āωāĻĒāĻžāĻĻāĻžāύ

Unit price: ā§ŗ2.05.
Strip price: ā§ŗ30.75 for 15 capsules.

Composition includes: Vitamins A, D3, C, B1, B2, B3, B5, B6, B12 and E.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāϤāĻŋ āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ ⧍.ā§Ļā§Ģ āϟāĻžāĻ•āĻž; ā§§ā§ĢāϟāĻŋāϰ āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ ā§Šā§Ļ.ā§­ā§Ģ āϟāĻžāĻ•āĻžāĨ¤

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Replenishes vitamins needed for normal metabolic and cellular function.

āĻŦāĻžāĻ‚āϞāĻž: āĻļāϰ⧀āϰ⧇āϰ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻŦāĻŋāĻĒāĻžāĻ• āĻ“ āϕ⧋āώ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽā§‡ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āϏāϰāĻŦāϰāĻžāĻš āĻ•āϰ⧇āĨ¤

12. Drug Indications — āϕ⧋āύ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿ?

Vitamin deficiency and selected nutritional inadequacy.

āĻŦāĻžāĻ‚āϞāĻž: āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ⧇āϰ āϘāĻžāϟāϤāĻŋ āĻ“ āĻĒ⧁āĻˇā§āϟāĻŋāĻ—āϤ āĻ…āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤāϤāĻžā§ŸāĨ¤

13. Drug Interactions + Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

Assess interactions according to the exact vitamin formulation. Avoid in known hypersensitivity.

āĻŦāĻžāĻ‚āϞāĻž: āωāĻĒāĻžāĻĻāĻžāύ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤ āĻ…āĻ¨ā§āϝ āϏāĻžāĻĒā§āϞāĻŋāĻŽā§‡āĻ¨ā§āĻŸā§‡āϰ āϏāĻ™ā§āϗ⧇ āĻŽā§‹āϟ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ⧇āϰ āĻŽāĻžāĻ¤ā§āϰāĻž āĻšāĻŋāϏāĻžāĻŦ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Avoid excessive intake, especially with multiple supplements containing fat-soluble vitamins.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āĻžāϧāĻŋāĻ• āϏāĻžāĻĒā§āϞāĻŋāĻŽā§‡āĻ¨ā§āϟ āĻāĻ•āϏāĻ™ā§āϗ⧇ āϖ⧇āϞ⧇ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻ—ā§āϰāĻšāϪ⧇āϰ āĻā§āρāĻ•āĻŋ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž

One capsule daily is the MedEx-listed adult regimen.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒā§āϰāĻžāĻĒā§āϤāĻŦ⧟āĻ¸ā§āĻ•āĻĻ⧇āϰ āĻĻ⧈āύāĻŋāĻ• āĻāĻ•āϟāĻŋ āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞāĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Use an appropriately selected supplement according to pregnancy or lactation needs.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ⧇āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āωāĻĒāϝ⧁āĻ•ā§āϤ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋ āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āĻ•āϰāϤ⧇ āĻšā§ŸāĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

Supravit-G and Supravit-S are different multivitamin–multimineral formulations, not identical substitutes.

āĻŦāĻžāĻ‚āϞāĻž: Supravit-G āĻ“ Supravit-S-āĻāϰ āωāĻĒāĻžāĻĻāĻžāύ āφāϞāĻžāĻĻāĻž, āϤāĻžāχ āĻāĻ•āχ āĻ“āώ⧁āϧ āĻŽāύ⧇ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

🟧 Clinical Verdict

Supportive nutritional therapy, not definitive treatment for genital ulcer disease.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒ⧁āĻˇā§āϟāĻŋāϰ āϘāĻžāϟāϤāĻŋāϤ⧇ āϏāĻšāĻžā§ŸāĻ•; āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āĻŦāĻž STI-āĻāϰ āĻŽā§‚āϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύ⧟āĨ¤

Drug confidence: 0.99.
Patient-specific indication confidence: 0.45.

Source:


🟧 SECTION 11. BANGLADESH DRUG COMPARISON TABLE

Table 2 — Disease-Specific Common Drug Options

Important: The following table presents examples of Bangladesh-listed drugs for relevant confirmed conditions. It is not a recommendation to give every medicine to this patient.

No.Disease/ConditionGenericBangladesh ExampleWhy Used
1Primary/secondary syphilisBenzathine benzylpenicillinBenzapenFirst-line penicillin treatment
2Genital herpesAcyclovirAcerux, Clovir, Simplovir, ViruxInhibits HSV replication
3Genital herpesValacyclovirAvailable valacyclovir preparationsAlternative systemic antiviral
4Superficial bacterial infectionMupirocinMuronLocal antibacterial treatment
5Selected bacterial skin infectionsCephalexinAvailable cephalexin preparationsOral antibacterial treatment when indicated
6Confirmed fungal balanitisClotrimazoleClotrimTopical antifungal treatment
7Severe resistant Gram-positive infectionLinezolidLinzolidRestricted systemic antibacterial treatment
8Allergic/pruritic rashFexofenadineFenadinSymptom relief only

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āĻāϏāĻŦ āϰ⧋āϗ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻœā§‡āύ⧇āϰāĻŋāĻ• āĻ“ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āϰ⧋āĻ— āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻ›āĻžā§œāĻž āĻāĻ•āϏāĻ™ā§āϗ⧇ āϏāĻŦ āĻ“āώ⧁āϧ āĻĻ⧇āĻ“ā§ŸāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Relevant Guideline Regimens

Early syphilis: Benzathine penicillin G 2.4 million units IM, once for appropriately staged primary or secondary syphilis.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āĻŦāĻž āϏ⧇āϕ⧇āĻ¨ā§āĻĄāĻžāϰāĻŋ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāϰāĻŋāĻ¸ā§āĻĨāĻŋāϤāĻŋāϤ⧇ āĻŦ⧇āύāϜāĻžāĻĨāĻŋāύ āĻĒ⧇āύāĻŋāϏāĻŋāϞāĻŋāύ āϜāĻŋ ⧍ā§Ē āϞāĻ•ā§āώ āχāωāύāĻŋāϟ āĻāĻ•āĻŦāĻžāϰ āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋāϤ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāĨ¤

Late latent/unknown-duration syphilis: Different staging and treatment duration apply; the early-syphilis single-dose regimen must not be assumed sufficient.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āϗ⧇āϰ āĻŽā§‡ā§ŸāĻžāĻĻ āĻ…āϜāĻžāύāĻž āĻŦāĻž āĻĻ⧇āϰāĻŋāϤ⧇ āĻļāύāĻžāĻ•ā§āϤ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻŽā§‡ā§ŸāĻžāĻĻ āφāϞāĻžāĻĻāĻžāĨ¤

First episode genital herpes: Acyclovir 400 mg orally three times daily for 7–10 days, or an equivalent recommended antiviral regimen.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāĻĨāĻŽāĻŦāĻžāϰ⧇āϰ āĻœā§‡āύāĻŋāϟāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ⧇ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϏāĻŽā§Ÿā§‡āϰ āϜāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻ­āĻžāχāϰāĻžāϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

These are guideline reference regimens for confirmed or clinically strongly suspected disease, not an automatically applicable new prescription for this patient.

Evidence: CDC STI Treatment Guidelines.

Confidence in general guideline regimens: 0.99.


🟩 SECTION 12. DOCTOR’S Dx VS LIPU MED Dx COMPARISON

🟧 Doctor’s Documented Diagnosis

No definitive diagnosis is written in the prescription.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϏāϰāĻžāϏāϰāĻŋ āϕ⧋āύ⧋ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āϗ⧇āϰ āύāĻžāĻŽ āϞ⧇āϖ⧇āύāύāĻŋāĨ¤

Confidence: 0.99.

🟧 Doctor’s Possible Diagnostic Considerations

  1. Syphilis: VDRL was ordered — āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻŋāĻŦ⧇āϚāύāĻžā§Ÿ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  2. Bacterial infection: Linezolid and mupirocin were prescribed — āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϏāĻ¨ā§āĻĻ⧇āĻš āĻ•āϰāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  3. Allergic/pruritic component: Fexofenadine was prescribed — āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻŦāĻž āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻŦāĻŋāĻŦ⧇āϚāύāĻžā§Ÿ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  4. Nutritional inadequacy: Calcium and multivitamin were prescribed — āĻĒ⧁āĻˇā§āϟāĻŋāĻ—āϤ āϏāĻšāĻžā§ŸāϤāĻž āωāĻĻā§āĻĻ⧇āĻļā§āϝ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.50–0.85 for inferred clinical intentions.

🟩 LIPU MED Working Diagnosis

Undifferentiated Genital Ulcer Disease with Skin Rash — Rule Out Syphilis and Genital Herpes.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž āĻ“ āĻļāϰ⧀āϰ⧇ āĻ°â€ā§āϝāĻžāĻļ; āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ“ āĻšāĻžāϰāĻĒāĻŋāϏ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.99 for the clinical syndrome.

🟩 Similarities — āĻŽāĻŋāϞ

  • VDRL investigation is consistent with considering syphilis.
  • Both the original treatment choices and this assessment consider infectious causes.
  • Skin symptoms are clinically relevant in both assessments.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ“ āĻ“āώ⧁āϧ⧇āϰ āϧāϰāύ āĻĻ⧇āϖ⧇ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻžāϰ āχāĻ™ā§āĻ—āĻŋāϤ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

🟧 Differences — āĻ…āĻŽāĻŋāϞ

  • No physician-documented etiological diagnosis exists.
  • HSV evaluation is not recorded in the original prescription.
  • Linezolid requires stronger evidence of bacterial infection.
  • The original note lacks lesion morphology and focused sexual-health history.
  • Syphilis confirmatory testing and HIV screening are not recorded.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϰ⧋āϗ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āύāĻžāĻŽ āϞ⧇āϖ⧇āύāύāĻŋ; HSV āĻĒāϰ⧀āĻ•ā§āώāĻž, āĻ•ā§āώāϤ⧇āϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϤāĻĨā§āϝāĻ“ āύ⧇āχāĨ¤

Final Comparison

The evaluations are partially aligned regarding investigation of syphilis, but there is no documented physician diagnosis to establish diagnostic equivalence.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻŋāĻŦ⧇āϚāύāĻžāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻŽāĻŋāϞ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϤāĻŦ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• Dx āύāĻž āϞ⧇āĻ–āĻžā§Ÿ āĻĻ⧁āχāϟāĻŋ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻāĻ•āχ āĻŦāϞāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.99.


đŸŠē SECTION 13. TEN CLINICAL DECISION-MAKING MODULES

🟩 MODULE 1 — CLINICAL DECISION-MAKING ALGORITHM

English Meaning: A structured sequence of clinical decisions used to identify the likely disease and guide treatment.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϧāĻžāĻĒ⧇ āϧāĻžāĻĒ⧇ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύ⧇āĻ“ā§ŸāĻžāϰ āĻĒāĻĻā§āϧāϤāĻŋāĨ¤

Clinical Application

Genital ulcer → Focused examination → Evaluate syphilis/HSV and noninfectious causes → Obtain indicated tests → Determine need for same-day presumptive treatment → Review results and follow-up.

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āĻĒā§āϰāĻĨāĻŽā§‡ āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āϤāĻžāϰāĻĒāϰ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ āĻ…āĻĨāĻŦāĻž āĻ…āĻ¨ā§āϝ āϰ⧋āϗ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻĻ⧇āϖ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Patient-Specific Assessment

This patient has genital ulceration and rash, but no documented lesion morphology or laboratory results.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž āĻ“ āĻ°â€ā§āϝāĻžāĻļ āφāϛ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϘāĻžā§Ÿā§‡āϰ āϧāϰāύ āĻŦāĻž āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āϜāĻžāύāĻž āύ⧇āχāĨ¤

Evidence

CDC advises laboratory evaluation of genital ulcers and appropriate presumptive treatment when infectious syphilis or first-episode herpes is suspected.

āĻŦāĻžāĻ‚āϞāĻž: āĻœā§‹āϰāĻžāϞ⧋ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻ¨ā§āĻĻ⧇āĻš āĻĨāĻžāĻ•āϞ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āύāĻŽā§āύāĻž āϏāĻ‚āĻ—ā§āϰāĻšā§‡āϰ āĻĒāϰ āĻāĻ•āχ āĻĻāĻŋāύ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻļ⧁āϰ⧁ āĻ•āϰāĻžāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.98.


🟩 MODULE 2 — DIAGNOSTIC EVIDENCE & UNCERTAINTY

English Meaning: Assessment of which findings support a diagnosis and which missing data limit certainty.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻĒāĻ•ā§āώ⧇ āϕ⧀ āĻĒā§āϰāĻŽāĻžāĻŖ āφāϛ⧇ āĻāĻŦāĻ‚ āϕ⧋āύ āϤāĻĨā§āϝ⧇āϰ āĻ…āĻ­āĻžāĻŦ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āϏāĻŽā§āĻ­āĻŦ āύ⧟āĨ¤

Clinical Application

Separate confirmed symptoms from suspected disease causes.

Patient-Specific Assessment

Confirmed as documented complaints: Genital ulcer, rash, weakness.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž, āĻ°â€ā§āϝāĻžāĻļ āĻ“ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻžāϰ āĻ…āĻ­āĻŋāϝ⧋āĻ— āϞ⧇āĻ–āĻž āφāϛ⧇āĨ¤

Unconfirmed: Syphilis, herpes, bacterial infection.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ āĻ…āĻĨāĻŦāĻž āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āύāĻŋāĻļā§āϚāĻŋāϤ āĻšā§ŸāύāĻŋāĨ¤

Evidence Gap

No RPR/VDRL result, treponemal test, HSV PCR or focused lesion examination is available.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āĻ“ āϘāĻžā§Ÿā§‡āϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āĻĒāϰ⧀āĻ•ā§āώāĻž āύ⧇āχāĨ¤

Diagnostic Confidence

  • Clinical syndrome: 0.99
  • Syphilis differential relevance: 0.70
  • HSV differential relevance: 0.65
  • Secondary bacterial infection: 0.50

Important: These confidence values are qualitative judgments, not validated disease probabilities.


🟩 MODULE 3 — PRESCRIPTION SAFETY AUDIT

English Meaning: Systematic evaluation of medicine indication, dose, duration, interactions and monitoring.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āĻ“āώ⧁āϧ āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇, āĻ•āϤāĻĻāĻŋāύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻ•āϤāϟāĻž āύāĻŋāϰāĻžāĻĒāĻĻ āϤāĻž āϝāĻžāϚāĻžāχāĨ¤

Clinical Application

Review all six medicines individually and identify avoidable risks.

Patient-Specific Assessment

DrugSafety ConcernPriority
LinezolidPotentially prolonged use without documented bacterial indication; CBC monitoringHigh
FexofenadineConfirm itching/allergic indication and renal statusModerate
DexlansoprazoleAcid-related indication not documentedModerate
Coralcin-DDeficiency not documentedLow–Moderate
MupirocinVerify lesion type and durationModerate
SupravitSupportive therapy only; avoid unnecessary duplicationLow

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻŋāώ⧟ āĻšāϞ⧋ LinezolidāĨ¤ āĻāϟāĻŋ āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•āĨ¤ āĻ…āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻŦāĻž āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇ āϰāĻ•ā§āϤ⧇āϰ āϕ⧋āώ āĻ“ āĻĒā§āϞ⧇āϟāϞ⧇āϟ āĻ•āĻŽāĻžāϰ āĻŽāϤ⧋ āϏāĻŽāĻ¸ā§āϝāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Evidence

MedEx linezolid monograph recommends weekly CBC monitoring, particularly with treatment beyond two weeks.

Confidence: 0.99 for linezolid monitoring concern.


🟩 MODULE 4 — RED FLAGS & EMERGENCY REFERRAL

English Meaning: Identification of symptoms that may indicate serious disease or need urgent specialist/hospital evaluation.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āĻŦāĻŋāĻĒāĻœā§āϜāύāĻ• āϞāĻ•ā§āώāĻŖ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻž, āϝāĻžāϤ⧇ āϜāϰ⧁āϰāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĻ⧇āĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

Red Flags

Severe genital pain or swelling — āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āĻĒā§āϰāϚāĻŖā§āĻĄ āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻĢā§‹āϞāĻžāĨ¤

Rapidly spreading redness — āĻĻā§āϰ⧁āϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ›ā§œāĻŋā§Ÿā§‡ āĻĒ⧜āĻžāĨ¤

High fever or systemic toxicity — āωāĻšā§āϚ āĻœā§āĻŦāϰ āĻŦāĻž āϗ⧁āϰ⧁āϤāϰ āĻ…āϏ⧁āĻ¸ā§āĻĨāϤāĻžāĨ¤

Urinary retention — āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āφāϟāϕ⧇ āϝāĻžāĻ“ā§ŸāĻžāĨ¤

Tissue necrosis — āϟāĻŋāĻ¸ā§āϝ⧁ āĻ•āĻžāϞ⧋ āĻšā§Ÿā§‡ āύāĻˇā§āϟ āĻšāĻ“ā§ŸāĻžāĨ¤

Visual, auditory or neurological symptoms — āĻšā§‹āĻ–, āĻ•āĻžāύ āĻŦāĻž āĻ¸ā§āύāĻžā§Ÿā§āϰ āύāϤ⧁āύ āϏāĻŽāĻ¸ā§āϝāĻžāĨ¤

Patient-Specific Assessment

None of these red flags is documented; however, absence of documentation does not prove absence of the symptom.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻāϏāĻŦ āĻŦāĻŋāĻĒāĻœā§āϜāύāĻ• āϞāĻ•ā§āώāĻŖ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āϰ⧋āĻ—ā§€āϰ āĻāϏāĻŦ āϞāĻ•ā§āώāĻŖ āύ⧇āĻ‡â€”āĻāĻŽāύ āύāĻŋāĻļā§āϚ⧟āϤāĻž āĻĻ⧇āĻ“ā§ŸāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

Referral

Emergency department if acute severe infection or systemic deterioration is suspected.

āĻŦāĻžāĻ‚āϞāĻž: āϗ⧁āϰ⧁āϤāϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϞāĻ•ā§āώāĻŖ āĻĨāĻžāĻ•āϞ⧇ āϜāϰ⧁āϰāĻŋ āĻŦāĻŋāĻ­āĻžāϗ⧇ āĻĒāĻžāĻ āĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98.


🟩 MODULE 5 — EVIDENCE-BASED TREATMENT COMPARISON

English Meaning: Comparison of prescribed management with disease-specific guideline recommendations.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĻ⧇āĻ“ā§ŸāĻž āĻ“āώ⧁āϧ āφāĻ¨ā§āϤāĻ°ā§āϜāĻžāϤāĻŋāĻ• āĻ—āĻžāχāĻĄāϞāĻžāχāύ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āϗ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻ™ā§āϗ⧇ āĻ•āϤāϟāĻž āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖ āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Clinical Application

Determine whether treatment targets the underlying cause or merely symptoms.

Patient-Specific Assessment

Linezolid: May treat appropriate bacterial infections, but not the recommended treatment for syphilis or HSV.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ āĻšāϤ⧇ āĻĒāĻžāϰ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻž āĻšāĻžāϰāĻĒāĻŋāϏ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύ⧟āĨ¤

Fexofenadine: Symptomatic relief only.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻŦāĻž āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻ•āĻŽāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Mupirocin: Only appropriate when a relevant superficial bacterial infection exists.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¸ā§āĻĨāĻžāĻ¨ā§€ā§Ÿ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻĨāĻžāĻ•āϞ⧇ āωāĻĒāĻ•āĻžāϰ⧀āĨ¤

Other medicines: Supportive or unrelated to the principal genital-ulcer differential.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…āĻ¨ā§āϝ āĻ“āώ⧁āϧāϗ⧁āϞ⧋ āĻŽā§‚āϞ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ STI-āĻāϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύ⧟āĨ¤

Evidence

CDC syphilis and HSV guidance specifies disease-specific antibiotic and antiviral regimens.

Confidence: 0.99.


🟩 MODULE 6 — FOLLOW-UP & CLINICAL OUTCOMES

English Meaning: Scheduled reassessment of symptom resolution, adverse effects and treatment success.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻĒāϰ⧇ āϰ⧋āĻ—ā§€ āĻ•āϤāϟāĻž āϏ⧁āĻ¸ā§āĻĨ āĻšāĻšā§āϛ⧇āύ āĻ“ āϕ⧋āύ⧋ āϜāϟāĻŋāϞāϤāĻž āĻšāĻšā§āϛ⧇ āĻ•āĻŋ āύāĻž āϤāĻž āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖāĨ¤

Clinical Application

Reassess lesion healing, rash progression and treatment adverse effects.

Patient-Specific Follow-up Plan

Early clinical review: Prompt review after diagnostic testing and examination, with earlier reassessment if symptoms worsen.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ⧇āϰ āĻĒāϰ āĻĻā§āϰ⧁āϤ āĻĢāϞ⧋āφāĻĒ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

If linezolid is being taken: Review CBC/platelets and adverse effects; do not wait until the end of a prolonged course.

āĻŦāĻžāĻ‚āϞāĻž: Linezolid āϚāĻžāϞ⧁ āĻĨāĻžāĻ•āϞ⧇ CBC āĻ“ āĻĒā§āϞ⧇āϟāϞ⧇āϟāϏāĻš āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āϜāϰ⧁āϰāĻŋāĨ¤

If early syphilis is diagnosed and treated: CDC recommends clinical and serological review at 6 and 12 months in the standard adult pathway, adjusted for clinical circumstances.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āĻŦāĻž āϏ⧇āϕ⧇āĻ¨ā§āĻĄāĻžāϰāĻŋ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϞ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻĒāϰ⧇ āϏāĻžāϧāĻžāϰāĻŖāϤ ā§Ŧ āĻ“ ⧧⧍ āĻŽāĻžāϏ⧇ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰāĻ•ā§āϤāĻĒāϰ⧀āĻ•ā§āώāĻžāϏāĻš āĻĢāϞ⧋āφāĻĒ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

If genital HSV is diagnosed: Reassess healing and recurrence, with further treatment decisions according to clinical presentation.

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāϰāĻĒāĻŋāϏ āĻšāϞ⧇ āϘāĻž āĻļ⧁āĻ•āĻžāĻšā§āϛ⧇ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ āφāĻŦāĻžāϰ āĻšāĻšā§āϛ⧇ āĻ•āĻŋ āύāĻž āĻĻ⧇āĻ–āϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.97.


🟩 MODULE 7 — INVESTIGATION INTERPRETATION

English Meaning: Interpretation of diagnostic test results in their clinical context.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āϰ⧋āĻ—ā§€āϰ āϞāĻ•ā§āώāϪ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āϏāĻ āĻŋāĻ• āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύ⧇āĻ“ā§ŸāĻžāĨ¤

VDRL/RPR and Treponemal Test Interpretation

Result PatternPossible MeaningāĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž
RPR/VDRL reactive + treponemal reactiveSupports syphilis infection; stage and treatment history need assessmentāϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻĒāĻ•ā§āώ⧇, āϤāĻŦ⧇ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āύāĻž āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ
RPR/VDRL nonreactive + treponemal reactivePrevious treated infection, early infection or other possibilitiesāφāϗ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇ āĻ…āĻĨāĻŦāĻž āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĻ“ āĻšāϤ⧇ āĻĒāĻžāϰ⧇
RPR/VDRL reactive + treponemal nonreactiveBiological false-positive or discordant result; further evaluation neededāϭ⧁āϞ positive āĻŦāĻž āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻ…āĻŽāĻŋāϞ āĻšāϤ⧇ āĻĒāĻžāϰ⧇
Both nonreactiveSyphilis less likely, but very early infection may not be excludedāĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻĒ⧁āϰ⧋āĻĒ⧁āϰāĻŋ āĻŦāĻžāĻĻ āϝāĻžā§Ÿ āύāĻž
HSV PCR positive from lesionSupports genital HSV infectionāĻšāĻžāϰāĻĒāĻŋāϏ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻĒāĻ•ā§āώ⧇
HSV PCR negativeDoes not fully exclude HSV, particularly in older/healing lesionsāĻĒ⧁āϰ⧋āύ⧋ āĻŦāĻž āĻļ⧁āĻ•āĻŋā§Ÿā§‡ āφāϏāĻž āϘāĻžā§Ÿā§‡āĻ“ negative āĻšāϤ⧇ āĻĒāĻžāϰ⧇

Patient-Specific Assessment

No investigation results are available.

āĻŦāĻžāĻ‚āϞāĻž: āĻāχ āϰ⧋āĻ—ā§€āϰ CBC, VDRL āĻŦāĻž HSV āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāύāĻŋāĨ¤

Confidence: 0.99 for general interpretation principles.

Evidence: CDC Laboratory Recommendations, 2024.


🟩 MODULE 8 — PATIENT EDUCATION IN BANGLA

English Meaning: Clear communication about the condition, tests, treatment and prevention.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϰ⧋āĻ—ā§€āϕ⧇ āϏāĻšāϜ āĻ­āĻžāώāĻžā§Ÿ āϤāĻžāρāϰ āϰ⧋āĻ—, āĻĒāϰ⧀āĻ•ā§āώāĻž, āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ“ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻŦā§‹āĻāĻžāύ⧋āĨ¤

Patient Education

1. āϘāĻž āĻŽāĻžāύ⧇āχ āϝ⧌āύāĻŦāĻžāĻšāĻŋāϤ āϰ⧋āĻ— āύ⧟āĨ¤ āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻ•āĻžāϰāϪ⧇ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

2. āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻāĻŦāĻ‚ āĻšāĻžāϰāĻĒāĻŋāϏ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāĻž āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤ āĻļ⧁āϧ⧁ āϘāĻž āĻĻ⧇āϖ⧇ āϰ⧋āĻ— āύāĻŋāĻ°ā§āϪ⧟ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

3. āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āύāĻž āφāϏāĻž āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āϘāĻžā§Ÿā§‡āϰ āĻ•āĻžāϰāĻŖ āύāĻŋāĻļā§āϚāĻŋāϤ āĻŦāϞāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

4. āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ›āĻžā§œāĻž āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ• āĻ–āĻžāĻ“ā§ŸāĻž āĻŦāĻž āĻ•ā§āώāϤ⧇ āύāĻžāύāĻž āϧāϰāύ⧇āϰ āĻ•ā§āϰāĻŋāĻŽ āϞāĻžāĻ—āĻžāύ⧋ āωāϚāĻŋāϤ āύ⧟āĨ¤

5. āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āĻĨāĻžāĻ•āϞ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻļ⧇āώ āύāĻž āĻšāĻ“ā§ŸāĻž āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āϝ⧌āύāϏāĻŽā§āĻĒāĻ°ā§āĻ• āĻā§œāĻžāύ⧋ āωāϚāĻŋāϤāĨ¤

6. āϝ⧌āύāĻŦāĻžāĻšāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻļāύāĻžāĻ•ā§āϤ āĻšāϞ⧇ āϏāĻ™ā§āĻ—ā§€āϰ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

7. āĻœā§āĻŦāϰ, āĻĒā§āϰāϚāĻŖā§āĻĄ āĻŦā§āϝāĻĨāĻž, āĻĢā§‹āϞāĻž āĻ…āĻĨāĻŦāĻž āϘāĻž āĻĻā§āϰ⧁āϤ āĻ›ā§œāĻŋā§Ÿā§‡ āϗ⧇āϞ⧇ āϜāϰ⧁āϰāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

8. āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāϏāĻš āĻĢāϞ⧋āφāĻĒ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Patient-Specific Assessment

The patient should receive confidential STI counselling and clear instructions about testing, follow-up and antibiotic safety.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϕ⧇ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āĻ—ā§‹āĻĒāĻ¨ā§€ā§ŸāϤāĻž āĻŦāϜāĻžā§Ÿ āϰ⧇āϖ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻĻ⧇āĻ“ā§ŸāĻž āωāϚāĻŋāϤāĨ¤

Confidence: 0.99.


🟩 MODULE 9 — GUIDELINE UPDATE & EVIDENCE QUALITY

English Meaning: Review of the most relevant available guidelines and assessment of the strength and applicability of evidence.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻ“ āĻ—āĻŦ⧇āώāĻŖāĻžāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ•āϤāϟāĻž āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝ āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Guideline Sources

CDC STI Treatment Guidelines, 2021

Relevant to genital ulcer evaluation, syphilis and genital herpes.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž, āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ“ āĻšāĻžāϰāĻĒāĻŋāϏ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

CDC Laboratory Recommendations for Syphilis Testing, 2024

Relevant to interpretation of syphilis serology.

āĻŦāĻžāĻ‚āϞāĻž: VDRL/RPR āĻ“ treponemal test-āĻāϰ āϏāĻ āĻŋāĻ• āĻŦā§āϝāĻžāĻ–ā§āϝāĻžāĨ¤

WHO Guidelines for Management of Symptomatic STIs, 2021

Relevant to syndromic management, including resource-limited settings.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϏ⧁āϝ⧋āĻ— āϏ⧀āĻŽāĻŋāϤ āĻšāϞ⧇ āωāĻĒāϏāĻ°ā§āĻ—āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• STI āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāĻĒāύāĻžāĨ¤

NIH Syphilis Guidance, updated 27 May 2026

Provides updated syphilis information, especially in the context of HIV care.

āĻŦāĻžāĻ‚āϞāĻž: HIV-āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ⧇āϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϤāĻĨā§āϝāĨ¤

Evidence Quality Assessment

EvidenceQuality/AppplicabilityConfidence
CDC laboratory testing recommendationsHigh applicability to diagnostic interpretation0.99
CDC syphilis/HSV treatment guidanceHigh applicability to disease-specific management0.99
WHO syndromic STI managementHigh relevance in resource-limited settings0.98
MedEx brand monographsUseful for Bangladesh brand/pricing; not sufficient alone for prescribing decisions0.98
Prescription aloneLimited evidence for etiological diagnosis0.99

Critical Evidence Limitation

No patient-specific laboratory confirmation exists in the supplied material.

āĻŦāĻžāĻ‚āϞāĻž: āφāĻ¨ā§āϤāĻ°ā§āϜāĻžāϤāĻŋāĻ• āĻ—āĻžāχāĻĄāϞāĻžāχāύ āϝāϤ āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀āχ āĻšā§‹āĻ•, āĻāχ āϰ⧋āĻ—ā§€āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āĻ›āĻžā§œāĻž āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ— āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Overall confidence: 0.99.

Sources:


🟩 MODULE 10 — MEDICAL SEO & ARTICLE TRANSPARENCY

English Meaning: Accurate presentation of medical information for publication, with transparent evidence, uncertainty and authorship.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻŦāĻŋāώ⧟āĻ• āϤāĻĨā§āϝ āύāĻŋāĻ°ā§āϭ⧁āϞāĻ­āĻžāĻŦ⧇ āĻĒā§āϰāĻ•āĻžāĻļ āĻ•āϰāĻž, āĻ—āĻŦ⧇āώāĻŖāĻžāϰ āϏ⧂āĻ¤ā§āϰ āĻĻ⧇āĻ“ā§ŸāĻž āĻāĻŦāĻ‚ āĻ…āύāĻŋāĻļā§āϚāĻŋāϤ āĻŦāĻŋāώ⧟ āĻ¸ā§āĻĒāĻˇā§āϟ āϰāĻžāĻ–āĻžāĨ¤

SEO Title

Genital Ulcer with Skin Rash: Syphilis vs Genital Herpes — Diagnosis, Tests and Treatment | LIPU MED

āĻŦāĻžāĻ‚āϞāĻž SEO āĻļāĻŋāϰ⧋āύāĻžāĻŽ

āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž āĻ“ āĻļāϰ⧀āϰ⧇ āĻ°â€ā§āϝāĻžāĻļ: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āύāĻžāĻ•āĻŋ āĻšāĻžāϰāĻĒāĻŋāϏ? āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟, āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž

Meta Description

A bilingual, evidence-based clinical review of genital ulcer disease with skin rash, including syphilis and herpes differential diagnosis, diagnostic testing, MedEx medication review and guideline-based management.

āĻŦāĻžāĻ‚āϞāĻž Meta Description

āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž āĻ“ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ°â€ā§āϝāĻžāĻļ⧇āϰ āĻ•āĻžāϰāĻŖ, āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ“ āĻšāĻžāϰāĻĒāĻŋāϏ⧇āϰ āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ, āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻž, āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻāĻŦāĻ‚ āĻ—āĻžāχāĻĄāϞāĻžāχāύāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

Suggested SEO Keywords

Genital Ulcer Disease, Syphilis, Genital Herpes, VDRL, Skin Rash, Linezolid, Mupirocin, STI Bangladesh, LIPU MED.

Transparency Statement

This article is based on one handwritten prescription. The reported symptoms are documented, but a definitive etiological diagnosis has not been established.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāϤāĻŋāĻŦ⧇āĻĻāύāϟāĻŋ āĻāĻ•āϟāĻŋ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĨ⧇āϕ⧇ āϤ⧈āϰāĻŋāĨ¤ āϰ⧋āĻ—ā§€āϰ āĻ…āĻ­āĻŋāϝ⧋āĻ— āϞ⧇āĻ–āĻž āĻĨāĻžāĻ•āϞ⧇āĻ“ āϰ⧋āϗ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ•āĻžāϰāĻŖ āĻāĻ–āύ⧋ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

Patient Privacy

Before publishing identifiable patient information, obtain documented consent and comply with applicable privacy requirements.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āφāϗ⧇ āϤāĻžāρāϰ āϞāĻŋāĻ–āĻŋāϤ āϏāĻŽā§āĻŽāϤāĻŋ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Clinical SEO Confidence

0.98 for accuracy of proposed terminology and transparent presentation.


🟧 SECTION 14. EVIDENCE-BASED MANAGEMENT / TREATMENT

Step 1 — Focused Clinical Examination

Perform appropriate genital, skin and lymph-node examination.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž, āĻ¤ā§āĻŦāϕ⧇āϰ āĻ°â€ā§āϝāĻžāĻļ āĻāĻŦāĻ‚ āϕ⧁āρāϚāĻ•āĻŋāϰ āϞāĻŋāĻŽā§āĻĢ āύ⧋āĻĄ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.99.

Step 2 — Diagnostic Testing

Obtain syphilis serology, treponemal confirmation, HSV testing and HIV screening as clinically indicated.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ, āĻšāĻžāϰāĻĒāĻŋāϏ āĻ“ HIV-āĻāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98.

Step 3 — Decide Whether Presumptive Treatment Is Needed

When clinical suspicion for infectious syphilis or first-episode genital HSV is sufficiently strong, guidelines support prompt clinician-directed presumptive treatment following appropriate specimen collection.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻŦāĻž āĻĒā§āϰāĻĨāĻŽāĻŦāĻžāϰ⧇āϰ āĻšāĻžāϰāĻĒāĻŋāϏ⧇āϰ āĻœā§‹āϰāĻžāϞ⧋ āϏāĻ¨ā§āĻĻ⧇āĻš āĻĨāĻžāĻ•āϞ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻž āύ⧇āĻ“ā§ŸāĻžāϰ āĻĒāϰ āϰāĻŋāĻĒā§‹āĻ°ā§āĻŸā§‡āϰ āϜāĻ¨ā§āϝ āĻ…āϝāĻĨāĻž āĻ…āĻĒ⧇āĻ•ā§āώāĻž āύāĻž āĻ•āϰ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻļ⧁āϰ⧁ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤

Confidence: 0.98.

Step 4 — Review Antibiotic Use

Reassess linezolid indication, dosage, duration and safety monitoring.

āĻŦāĻžāĻ‚āϞāĻž: Linezolid āϏāĻ¤ā§āϝāĻŋāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ āĻ•āϤāĻĻāĻŋāύ āύāĻŋāϰāĻžāĻĒāĻĻ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āϤāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.99.

Step 5 — Follow-up

Review results, lesion healing, adverse effects and need for specialist care.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ, āϘāĻž āĻļ⧁āĻ•āĻžāύ⧋āϰ āĻ…āĻ—ā§āϰāĻ—āϤāĻŋ āĻāĻŦāĻ‚ āĻ“āώ⧁āϧ⧇āϰ āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98.


🟧 SECTION 15. SAMPLE CLINICAL PRESCRIPTION / CASE NOTE

EDUCATIONAL DEMONSTRATION — NOT A VALID SIGNED PRESCRIPTION

Patient Name: Nazem Ali
Age: 52 years
Sex: Male
Weight: 65 kg
Original Consultation Date: 20 October 2026

C/C

  1. Generalized weakness — āϏāĻžāĻ°ā§āĻŦāĻŋāĻ• āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻžāĨ¤
  2. Genital ulcer — āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻžāĨ¤
  3. Skin rash — āĻ¤ā§āĻŦāϕ⧇ āĻ°â€ā§āϝāĻžāĻļāĨ¤

O/E

Original O/E: NAD.

BP: Approximately 130/80 mmHg.

Genital examination: Not documented.

Skin examination: Not documented.

Lymph-node examination: Not documented.

Dx

1. Undifferentiated Genital Ulcer Disease (GUD).

2. Associated Cutaneous Rash.

3. Generalized Weakness.

4. R/O Syphilis and Genital HSV Infection.

5. ?Secondary Superficial Bacterial Infection.

āĻŦāĻžāĻ‚āϞāĻž Dx

ā§§. āĻ•āĻžāϰāĻŖ āĻ…āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻžāĨ¤

⧍. āϏāĻ™ā§āϗ⧇ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ°â€ā§āϝāĻžāĻļāĨ¤

ā§Š. āϏāĻžāĻ°ā§āĻŦāĻŋāĻ• āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻžāĨ¤

ā§Ē. āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ“ āĻšāĻžāϰāĻĒāĻŋāϏ āĻŦāĻžāĻĻ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

ā§Ģ. āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

Investigation Plan

  • CBC with platelet count.
  • Quantitative RPR/VDRL.
  • Treponemal assay (TPPA/EIA).
  • HSV-1/HSV-2 PCR from lesion, if available.
  • HIV Ag/Ab test.
  • Glucose/HbA1c if clinically indicated.
  • Additional testing according to lesion findings.

Rx Decision

Definitive antimicrobial regimen: To be determined after appropriate clinical assessment and diagnostic evaluation.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώāϤ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āϤāĻĨā§āϝ āϏāĻ‚āĻ—ā§āϰāĻšā§‡āϰ āĻĒāϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ• āĻŦāĻž āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻ­āĻžāχāϰāĻžāϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ āĻŋāĻ• āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Existing linezolid therapy requires prescriber review; this case note does not authorize independent discontinuation or substitution.

Advice

Maintain gentle local hygiene — āĻ•ā§āώāϤāĻ¸ā§āĻĨāĻžāύ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āϰāĻžāĻ–āĻžāĨ¤

Avoid irritating topical products — āĻ…āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻ•ā§āϰāĻŋāĻŽ āĻŦāĻž āϰāĻžāϏāĻžā§ŸāύāĻŋāĻ• āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻž āĻ•āϰāĻžāĨ¤

Avoid sexual contact pending appropriate evaluation and treatment — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ“ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻļ⧇āώ āύāĻž āĻšāĻ“ā§ŸāĻž āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āϝ⧌āύāϏāĻŽā§āĻĒāĻ°ā§āĻ• āĻā§œāĻžāύ⧋āĨ¤

Follow up promptly — āĻĻā§āϰ⧁āϤ āĻĢāϞ⧋āφāĻĒāĨ¤

Seek urgent care for red flags — āĻŦāĻŋāĻĒāĻœā§āϜāύāĻ• āϞāĻ•ā§āώāĻŖ āĻĻ⧇āĻ–āĻž āĻĻāĻŋāϞ⧇ āϜāϰ⧁āϰāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

Demo clinical note confidence: 0.99 for accurate representation of available data and uncertainty.


🟧 SECTION 16. SPECIALIST REFERRAL

Primary Referral

Dermatologist / Dermatovenereologist — āϚāĻ°ā§āĻŽ āĻ“ āϝ⧌āύāϰ⧋āĻ— āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžāĨ¤

Reason: Genital ulcer with skin rash and possible STI.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž āĻ“ āĻļāϰ⧀āϰ⧇ āĻ°â€ā§āϝāĻžāĻļ⧇āϰ āĻ•āĻžāϰāĻŖ āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡ āϚāĻ°ā§āĻŽ āĻ“ āϝ⧌āύāϰ⧋āĻ— āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžā§‡āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.99.

Additional Referral

Infectious Disease Specialist — āϏāĻ‚āĻ•ā§āϰāĻžāĻŽāĻ• āϰ⧋āĻ— āĻŦāĻŋāĻļ⧇āώāĻœā§āĻž: Complex STI, treatment failure or confirmed coinfection.

āĻŦāĻžāĻ‚āϞāĻž: āϜāϟāĻŋāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āωāĻ¨ā§āύāϤāĻŋ āύāĻž āĻšāϞ⧇āĨ¤

Urologist — āχāωāϰ⧋āϞāϜāĻŋāĻ¸ā§āϟ: Persistent suspicious penile lesion or urinary complication.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āϘāĻž āĻ…āĻĨāĻŦāĻž āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇āϰ āϜāϟāĻŋāϞāϤāĻž āĻĨāĻžāĻ•āϞ⧇āĨ¤

Medicine Specialist — āĻŽā§‡āĻĄāĻŋāϏāĻŋāύ āĻŦāĻŋāĻļ⧇āώāĻœā§āĻž: Significant unexplained weakness or systemic illness.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻŦāĻž āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āϰ⧋āϗ⧇āϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āĨ¤

Confidence: 0.95.


🟩 SECTION 17. OVERVIEW / SUMMARY

Final Clinical Assessment

The patient presents with physician-documented generalized weakness, genital ulceration and skin rash. The supplied prescription does not contain a definitive diagnosis or laboratory results. Syphilis and genital herpes are important differential diagnoses, while secondary bacterial infection remains possible but unconfirmed.

āĻŦāĻžāĻ‚āϞāĻž āϏāĻžāϰāϏāĻ‚āĻ•ā§āώ⧇āĻĒ

āϰ⧋āĻ—ā§€āϰ āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āϘāĻž, āĻļāϰ⧀āϰ⧇ āĻ°â€ā§āϝāĻžāĻļ āĻāĻŦāĻ‚ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻžāϰ āĻ…āĻ­āĻŋāϝ⧋āĻ— āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• VDRL āĻ“ CBC āĻĒāϰ⧀āĻ•ā§āώāĻž āĻĻāĻŋā§Ÿā§‡āϛ⧇āύāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āĻāĻŦāĻ‚ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ Dx āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤

āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻ“ āĻœā§‡āύāĻŋāϟāĻžāϞ āĻšāĻžāϰāĻĒāĻŋāϏ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āĨ¤ āϤāĻŦ⧇ āϕ⧋āύ⧋āϟāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

Linezolid-āĻāϰ āĻŽāϤ⧋ āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāϕ⧇āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻāĻŦāĻ‚ āĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻŦāĻŋāĻļ⧇āώāĻ­āĻžāĻŦ⧇ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Final Prescription-Ready Dx

Dx: Undifferentiated Genital Ulcer Disease with Associated Skin Rash — R/O Syphilis and Genital HSV Infection; ?Secondary Bacterial Infection.

Confidence in working syndromic diagnosis: 0.99.

Definitive etiological diagnosis: Pending clinical examination and investigations.


🟩 ACTIONABLE CLINICAL PLAN

1. Immediate priority: Focused genital and skin examination.

āĻŦāĻžāĻ‚āϞāĻž: āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āϘāĻž āĻ“ āĻ°â€ā§āϝāĻžāĻļ āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻžāĨ¤

2. Diagnostic priority: Syphilis serology and appropriate treponemal confirmation; HSV and HIV testing.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ STI āĻĒāϰ⧀āĻ•ā§āώāĻžāĨ¤

3. Medication priority: Review linezolid indication and CBC monitoring.

āĻŦāĻžāĻ‚āϞāĻž: Linezolid-āĻāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻ“ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āϝāĻžāϚāĻžāχāĨ¤

4. Specialist priority: Dermatovenereology referral.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻ°ā§āĻŽ āĻ“ āϝ⧌āύāϰ⧋āĻ— āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžā§‡āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļāĨ¤

5. Follow-up priority: Review laboratory results, lesion healing and treatment response.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻ…āĻ—ā§āϰāĻ—āϤāĻŋ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĢāϞ⧋āφāĻĒāĨ¤

Overall confidence: 0.98.


🟧 REFERENCE LIST

A. Medical Textbooks

1. Harrison’s Principles of Internal Medicine. 21st edition. McGraw Hill; 2022.

Relevant topics: Syphilis, herpesvirus infections and infectious disease evaluation.

2. Davidson’s Principles and Practice of Medicine. 24th edition. Elsevier; 2022.

Relevant topics: Sexually transmitted infections, skin disease and systemic infection.

3. Andrews’ Diseases of the Skin: Clinical Dermatology. 14th edition. Elsevier; 2024.

Relevant topics: Genital dermatoses, bacterial skin infections and dermatological diagnosis.

4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th edition. McGraw Hill; 2022.

Relevant topics: Antibacterial agents, antihistamines, PPIs and pharmacological safety.

Note: Exact textbook page numbers have not been independently verified and are therefore not supplied.

B. International Guidelines

5. CDC. Sexually Transmitted Infections Treatment Guidelines. 2021.

Genital ulcer disease, syphilis and genital herpes.

CDC — Genital Ulcer Disease Guidelines

6. WHO. Guidelines for the Management of Symptomatic Sexually Transmitted Infections. 2021.

WHO — STI Management Guidelines

7. CDC. Laboratory Recommendations for Syphilis Testing, United States. 2024.

CDC — Syphilis Laboratory Testing Recommendations

8. NIH. Syphilis: Adult and Adolescent Opportunistic Infection Guidelines. Updated 27 May 2026.

NIH — Syphilis Guidance

9. IDSA. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections. 2014.

IDSA — Skin and Soft Tissue Infection Guideline

C. Peer-Reviewed Journals with Verified DOI

10. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1–187.

DOI: 10.15585/mmwr.rr7004a1

11. Papp JR, Park IU, Fakile Y, et al. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recommendations and Reports. 2024;73(1):1–32.

DOI: 10.15585/mmwr.rr7301a1

12. Hook EW III. Syphilis. The Lancet. 2017;389(10078):1550–1557.

DOI: 10.1016/S0140-6736(16)32411-4

13. Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by IDSA. Clinical Infectious Diseases. 2014;59(2):e10–e52.

DOI: 10.1093/cid/ciu296

D. Bangladesh Drug Reference

MedEx Bangladesh — medex.com.bd

Drug-specific MedEx links are provided separately under each of the six prescribed medicines.


🟩 FINAL AUTHOR & PUBLICATION INFORMATION

Author Name: Md.Rafiqul Islam Lipu

Publication Date: Monday, 2 November 2026

āĻŦāĻžāĻ‚āϞāĻž: āϏ⧋āĻŽāĻŦāĻžāϰ, ⧍ āύāϭ⧇āĻŽā§āĻŦāϰ ⧍ā§Ļ⧍ā§ŦāĨ¤

Time Verified: 1:24 PM, Bangladesh Standard Time (UTC+06:00)

Website: raiyyantahsan.com

Department: Dermatology & Venereology

Proposed TC Number: 1485

DCS: 02

Proposed Dermatology Department Case Number: 106

Article Type: Full Bilingual Clinical Case Analysis.

Content: 1 Prescription + 0 Reports + 0 Clinical Images.

Drug Review: 6 Individual Medicines × 17 Parameters = 102 Medicine Review Parameters.

Clinical Decision-Making Modules: 10 Complete Modules.

Article Size: Extended bilingual article, approximately 5,000–6,500 words. This is an editorial estimate rather than an automated count.

Publication Status: Draft — not yet published.

Clinical Disclaimer: This is a prescription-based clinical review and educational working assessment. The exact disease cause is not established without appropriate clinical examination and investigations.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top